Stockwinners Market Radar for February 27, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:07 EST Cathie Wood's ARK Investment bought 196K shares of Roblox today

20:01 EST Omega Therapeutics chairman Afeyan buys $19.2M in common stock - In a regulatory filing, Omega Therapeutics disclosed that the firm of its chairman Noubar Afeyan, Flagship Pioneering, bought 3.3M shares of common stock on February 27th in a total transaction size of $19.2M. Shares of Omega Therapeutics are up 10.6% afterhours at $6.45 per share.

19:21 EST Twilio CEO buys $10.0M in common stock - In a regulatory filing, Twilio disclosed that its CEO Jeff Lawson bought 158K shares of common stock on February 24th in a total transaction size of $10.0M. Shares of Twilio are up 3.9% afterhours at $66.25.

19:17 EST Aris Water says ExxonMobil added to water reuse agreement - Aris Water Solutions, Inc. (ARIS) announced that ExxonMobil (XOM) has joined Aris's previously announced strategic agreement with Chevron U.S.A. Inc. (CVX) and ConocoPhillips Company (COP) to develop and pilot technologies and processes to treat produced water for potential beneficial reuse opportunities. Together, Aris, ExxonMobil, Chevron, and ConocoPhillips seek to develop cost-effective and scalable solutions of treating produced water for non-consumptive agricultural, alternative power generation and other industrial and commercial applications, the company said. "We are delighted that ExxonMobil is joining our collaborative industry efforts to improve water sustainability management in the Permian Basin by developing and piloting additional opportunities to use produced water outside of the oil and gas industry," said Aris President and CEO Amanda Brock. "By combining the expertise and resources of ExxonMobil, Chevron, and ConocoPhillips with Aris's proven capabilities in water gathering, treatment, and recycling, we can further accelerate beneficial reuse solutions."

18:10 EST Singularity Future Technology discloses further Nasdaq listing compliance notice - Singularity Future Technology "announced that on February 21, 2023, it received an additional staff determination notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC , advising that it had not received the Company's Form 10-Q for the quarterly period ended December 31, 2022, which served as an additional basis for delisting the Company's securities and that the Nasdaq Hearings Panel will consider the additional deficiency in rendering a determination regarding the Company's continued listing on Nasdaq. The Company has submitted to the Panel a plan to regain compliance with the continued listing requirements and has been granted a grace period to file all the delinquent reports, including the filing of the Form 10-Q for the quarterly period ended December 31, 2022, on or before February 28, 2023."

17:45 EST Globalstar announces Spain authorization for terrestrial services - Globalstar announced that Spain has authorized the company to provide complementary terrestrial services, over its mobile satellite spectrum including LTE and 5G compliant services via Band 53/n53. This marks a major step forward in the convergence of satellite and mobile terrestrial services to connect and protect both lives and property globally.

17:29 EST CEA Industries announces cost saving initiatives - CEA Industries "announced cost saving initiatives that include various operating expense reductions and a reduction in force in response to continued macroeconomic and supply chain challenges. In recent quarters the Company has experienced declining activity due to weakness in the macroeconomic environment of the cannabis market, which is facing increasing competition and declining wholesale prices as consumers become more sophisticated and selective when choosing products. The overall controlled environment agriculture market is also experiencing a fluctuating economy, rising costs, and the fear of recession that is delaying, reducing or eliminating capital projects. Additionally, the Company faces continued supply chain, labor and inflationary issues that are impacting customers' contract decisions and implementation. At this stage, the Company concluded that a workforce reduction and the implementation of operating expense savings were necessary."

17:17 EST Mark Zuckerberg announces new team at Meta working on A.I. products - In a Facebook post, Mark Zuckerberg, announces new team at Meta working on A.I. products for Instagram, WhatsApp. The Meta CEO has created a new product group inside the company focused on generative AI. The post said: "We're creating a new top-level product group at Meta focused on generative AI to turbocharge our work in this area. Were starting by pulling together a lot of the teams working on generative AI across the company into one group focused on building delightful experiences around this technology into all of our different products. In the short term, we'll focus on building creative and expressive tools. Over the longer term, we'll focus on developing AI personas that can help people in a variety of ways. We're exploring experiences with text (like chat in WhatsApp and Messenger), with images (like creative Instagram filters and ad formats), and with video and multi-modal experiences. We have a lot of foundational work to do before getting to the really futuristic experiences, but I'm excited about all of the new things we'll build along the way." Reference Link

17:04 EST Waymo debuts fully-autonomous testing in in Los Angeles - Dmitri Dolgov, the co-chief executive officer of Waymo, tweeted earlier: "Following a rigorous cycle of validation and safety readiness evaluation, @Waymo is starting fully-autonomous (no human driver) testing in LA. Thrilled by the data confirming, once again, how well our ML-based 5th-gen Driver generalizes across cities!" The Fly notes that Waymo , formerly known as the Google Self-Driving Car Project, is an American autonomous driving technology company headquartered in Mountain View, California. It is a subsidiary of Alphabet (GOOG, GOOGL) the parent company of Google. Reference Link

17:00 EST Robinhood receives subpoena's from California AG over crypto trading - In a regulatory filing, Robinhood said its Crypto Matters division has received subpoenas from the California Attorney General's Office seeking information about, among other things, RHC's trading platform, business and operations, custody of customer assets, customer disclosures, and coin listings. RHC is cooperating with this investigation.

16:58 EST Strata Skin Sciences regains compliance with Nasdaq - STRATA Skin Sciences announced that it had been notified by Nasdaq that Strata has regained compliance with the Nasdaq listing requirements regarding minimum bid price, Rule 5550.

16:48 EST Rover Group announces $50M share buyback

16:38 EST Occidental Petroleum declares 18c per share quarterly dividend - Occidental announced that its board of directors has declared a regular quarterly dividend of 18c per share on common stock, payable on April 17 to stockholders of record as of the close of business on March 10.

16:35 EST Adamis Pharmaceuticals trading resumes

16:33 EST GigCapital5 confirms receipt of funds to extend period of time for transaction - GigCapital5 "announced that GigAcquisitions5, LLC has funded the trust account maintained with Continental Stock Transfer & Trust Company with an additional $160,000 payment. In consideration for the deposit, the Company has amended and restated the existing unsecured interest free promissory note to include the additional loan amount, so the aggregate principal amount under such promissory note together with similar deposits made on September 26, 2022, October 26, 2022, November 28, 2022, December 27, 2022, and January 25, 2023 was increased to the total of $960,000. Such principal amount will be repaid in connection with the closing of GigCapital5's initial business combination. As a result of the deposits into the Trust Account, the period of time that GigCapital5 has to consummate a business combination has been extended by a month to March 28, 2023."

16:31 EST Quaker Houghton names Jeffrey Fleck chief supply chain officer - Quaker Houghton announced that Jeffrey L. Fleck has joined the company as Senior Vice President and Chief Supply Chain Officer effective February 27, 2023. Fleck is responsible for leading the global end-to-end supply chain organization. Andy Tometich, Chief Executive Officer and President stated: "I am pleased to welcome Jeff to Quaker Houghton. He brings extensive leadership capabilities and supply chain expertise to optimize and strengthen our global footprint, operations and processes and further enable the Company to execute on our long-term growth strategy." Prior to joining Quaker Houghton, Fleck most recently served as Senior Vice President and Chief Supply Chain Officer for Georgia-Pacific Consumer Products Company from 2016 to 2023. From 2010 to 2015, Mr. Fleck was Senior Vice President and Chief Supply Chain and R&D Officer at Zep, Inc. Prior, he also held various supply chain management leadership positions at The Clorox Company, American Home Products, and Cargill Incorporated.

16:30 EST Amarin accuses Sarissa of making 'misstatements' - Amarin issued the following statement in response to Sarissa's latest misstatements regarding the company's management compensation: "The Amarin Board of Directors, consistent with standard public company practice and in line with its fiduciary responsibilities, authorized its management compensation plan for 2023. Contrary to Sarissa's claims, the timing of the plan approval was in February, which is consistent with previous years. In addition, as part of this year's compensation plan (like all prior years), all Amarin employees globally received annual performance grants. Sarissa's comment that Karim Mikhail's equity grants vest "solely based on the passage of time" is also another misrepresentation of the facts. Mr. Mikhail's compensation package includes performance-based grants, which are only triggered if performance thresholds are achieved. Sarissa also insinuates that the Board is "refusing" to release the results of the General Meeting - this is another misrepresentation of the facts. The General Meeting has not occurred yet, and Sarissa and its legal advisors both know that companies do not publicize preliminary results prior to any general meeting, consistent with SEC guidelines. The Board assures shareholders that the results of the General Meeting will be posted in a timely manner following the conclusion of the meeting. The New Amarin is on the right track toward transforming into a global, diversified cardiometabolic player as we execute a thoughtful and practical strategic plan designed to create value now."

16:25 EST Verrica: FDA accepts filing of VP-102 resubmitted NDA for molluscum treatment - Verrica Pharmaceuticals announced that the U.S. Food and Drug Administration FDA accepted for filing the Company's resubmitted New Drug Application NDA for VP-102 for the treatment of molluscum contagiosum and assigned a Prescription Drug User Fee Act PDUFA goal date of July 23. "We are pleased that the FDA has accepted for filing our NDA resubmission for VP-102," said Ted White, Verrica's President and Chief Executive Officer. "With no FDA-approved treatments for molluscum, the filing acceptance of our NDA brings us one step closer towards providing a safe and effective therapeutic treatment option for the millions of patients in the United States with molluscum. VP-102 has been designed for reliable and targeted administration of cantharidin through a unique, topical, GMP-controlled formulation through a single-use applicator. Based upon the strong safety and efficacy results from our two Phase 3 clinical trials, we believe that VP-102 has the potential to offer an important new treatment option for molluscum."

16:22 EST PSQ to go public through SPAC deal with Colombier Acquisition - PSQ Holdings and Colombier Acquisition Corp., a publicly traded special purpose acquisition company, announced that they have entered into a definitive business combination agreement. After the anticipated closing in the third quarter of 2023, the combined company will retain the PSQ Holdings, Inc. name and expects to trade on the New York Stock Exchange under the symbol PSQH. Colombier shares will continue to trade on the NYSE under the CLBR symbol until the closing of the transaction. Michael Seifert, the Founder and CEO of PublicSq., said: "For too long, progressive corporations have prioritized highly politicized ideas over the interests and values of the American people. Because of this, we, as patriotic Americans, are hungering for a future where the power is back in the hands of 'We the People' and a parallel economy is created. With the PublicSq. platform, we are grateful to provide a solution that helps every day, freedom-loving Americans spend their hard-earned money with businesses that prioritize the values that have made this nation so special in the first place. We're just getting started, and we're proud to partner with the Colombier team." PublicSq. will merge with a wholly owned subsidiary of Colombier, with PublicSq. continuing as the surviving entity in the merger. The Boards of Directors of PublicSq. and Colombier have each unanimously approved the transaction. The transaction will require the approval of the stockholders of Colombier and PublicSq. The transaction is subject to other customary closing conditions and is expected to close in the third quarter of 2023. Transaction consideration to PublicSq. holders will consist of newly issued shares with a value of $200 million, not including shares issuable pursuant to an earnout. The transaction is expected to provide up to $158.5 million in cash to PublicSq. to fund growth and expansion into new revenue streams, assuming no redemptions. Upon the closing of the transaction, Michael Seifert will retain majority voting rights and continue to drive PublicSq.'s mission of becoming the nation's leading values-aligned marketplace.

16:14 EST Ameresco acquires ENERQOS Energy Solutions - Ameresco "announced the signing of a definitive purchase and sale agreement to acquire ENERQOS Energy Solutions S.r.l., a renewable energy and energy efficiency company headquartered in Milan. With this acquisition, Ameresco will be able to expand its portfolio of clean energy projects and solutions throughout Italy. Enerqos has been operating for more than 15 years with the mission of taking care of the environment by offering a competitive advantage to Italian companies through energy efficiency and renewable energy solutions. They have a large portfolio of cost saving and carbon reduction projects across multiple markets in Italy, including healthcare, real estate, retail and residential."

16:13 EST Aptinyx to resume trading at 4:35pm E.T. - Quotation in Aptinyx will resume at 4:30pm E.T., acc Shares have been halted ahead of the company's announcement that its Phase 2 Study of NYX-458 did not demonstrate sufficient efficacy in patients with cognitive impairment associated with Parkinson's disease and dementia with Lewy bodies.

16:09 EST Trex Company sees FY23 EBITDA margin of 26%-27% - The company states: "With channel inventory recalibration completed by year-end 2022, we began 2023 strategically focused on our residential business, where we intend to drive accelerated wood conversion, reinforce our market leadership position, and continue to educate customers on the many advantages of the full range of Trex sustainable, high-performance, low-maintenance outdoor living products. To support these initiatives, we will continue to invest in the Trex brand and commercialize new products that broaden our market opportunity. Innovation remains a key competitive advantage for Trex. We recently announced the regional launch of our premium Trex Signature(R) decking product, which raises the bar for beauty, performance and sustainability with a whole new level of realism for wood plastic composite decking and is complemented by the full range of Trex Signature railing. We also doubled the number of color options available for our recently launched Trex Transcend(R) Lineage(TM) product line, which incorporates heat-mitigating technology. In addition, we introduced a tiered warranty structure for Trex decking that underscores the value of our good/better/best decking lineup. Our line-up for 2023 offers products at every price point designed to resonate with consumers seeking to optimize their outdoor living experience...We expect full year 2023 EBITDA margin to be in the 26% to 27% range. In the first two months of the 2023 first quarter, our plants were building to an annual revenue rate of one billion dollars. However, if demand is different than expected, we have the ability to quickly flex our production level. Capital expenditures for 2023 are anticipated to be in the $130 million to $140 million range, primarily related to the modular build out of our Arkansas facility calibrated to demand trends."

16:00 EST Aptinyx trading halted, news pending

15:23 EST Tesla temporarily halts FSD beta software installations until recall addressed - The company said in part on a customer suppoer page: "Tesla has issued a voluntary recall on certain Model S, Model 3, Model X and Model Y vehicles that have installed or pending installation of software that contains the Full Self-Driving, FSD, Beta feature. This recall affects only US and CA vehicles. Affected vehicles were identified based on vehicle manufacturing, configuration, and software records. A software update which includes the remedy that will improve how FSD Beta negotiates certain driving maneuvers during specific conditions will be deployed over-the-air ,OTA,to affected vehicles when the software is available. "FSD Beta is an SAE Level 2 driver support feature that can provide steering and braking/acceleration support to the driver under certain operating limitations. With FSD Beta, as with all SAE Level 2 driver support features, the driver is responsible for operation of the vehicle whenever the feature is engaged and must constantly supervise the feature and intervene, e.g., steer, brake or accelerate, as needed to maintain safe operation of the vehicle. In certain rare circumstances and within the FSD Beta operating limitations, when the feature is engaged, it could potentially infringe upon local traffic laws or customs while executing these driving maneuvers in specific conditions before the driver may intervene." Reference Link

14:31 EST Black Knight down 5% after Politico says FTC to challenge deal - Shares of Black Knight (BKI) are down about 5% to $60.05 after Politico reported, citing source, that the Federal Trade Commission is expected to challenge the takeover of the mortgage data company by Intercontinental Exchange (ICE). Three people with knowledge of the matter told Politico's Joshua Sisco that the FTC believes the deal would give Intercontinental Exchange, which also owns the NYSE, too much power in the U.S. mortgage market and that a case is expected to be filed some time in March.

14:06 EST Radius Global shares jump 20% after Bloomberg report of EQT deal

13:52 EST Radius Global Infrastructure trading halted, volatility trading pause

13:33 EST LumiraDx gets FDA EUA amendment for SARS-CoV-2 RNA STAR Complete test kit - LumiraDx gets FDA Emergency Use Authorization amendment for its SARS-CoV-2 RNA STAR Complete test kit to extend the shelf life to 12 months. According to the letter from the FDA, "This is to notify you that your request is granted to update the authorized labeling of the LumiraDx SARS-CoV-2 RNA STAR Complete to alternative catalogue numbers for the assay kit to reflect different formulations of the Negative Control Media, and extend the shelf-life of the LumiraDx SARS-CoV-2 RNA STAR Complete kit to 12 months when stored according to the authorized labeling. Upon review, we concur that the data and information submitted in EUA202584/S011 supports the requested updates for use with the LumiraDx SARS-CoV-2 RNA STAR Complete. By submitting this EUA revision for review by the Food and Drug Administration, you have complied with the Conditions of Authorization stated in the letter authorizing the emergency use of the LumiraDx SARS-CoV-2 RNA STAR Complete re-issued on February 18, 2022." Reference Link

13:16 EST Amazon to spend $200M on safety technology across transportation network in 2023 - Udit Madan, Vice President of Amazon Transportation wrote in part earlier: "Safety is integral to everything we do across our operations at Amazon, every day, in every country, and especially on the road. As we work to deliver for our customers, we continue to innovate and advance safety features in the trucks and vans we deploy, keeping the safety of our partners and communities where we deliver as our top priority. A challenge as complex as roadway safety requires strong leadership across both the public and private sectors. Amazon has helped lead the way in investments and innovations, and I'm proud to share some highlights of how Amazon is already working toward the goals outlined in the U.S. Department of Transportation's National Roadway Safety Strategy, NRSS . The examples below are each part of a $200M investment in new safety technology, and part of our continuing work to ensure Amazon vehicles and our delivery partners are safe on the road ...We've equipped our middle mile trucking network, which is responsible for shipping packages to and from our operations sites before they're dispatched for last mile delivery to customers, with leading safety technology, including automatic emergency braking, front-collision warning, stability control, lane-departure warning, side-object detection, adaptive cruise control, and speed limiters. Since 2017, ..we've invested heavily in our route planning navigation systems and predictive analytics software to better monitor fleet safety. All of this is embedded into our mobile technology, called Relay, that connects carriers and drivers to Amazon, and provides them with navigation assistance, real-time driver-facing alerts, safety performance summaries, and additional safety learning." Reference Link

12:17 EST TD Bank settles Stanford Financial litigation for $1.2B - TD Bank Group announced earlier today that it has agreed to a settlement in principle relating to litigation involving the Stanford Financial Group. Upon final approval of the settlement by the Court, TD will pay $1.205B to the court-appointed receiver for the Stanford Receivership Estate. Under the terms of the agreement, TD has settled with the receiver, the Official Stanford Investors Committee, and other plaintiffs in the litigation and these parties have agreed to a bar order dismissing and releasing all current or future claims arising from or related to the Stanford matter. TD "expressly denies any liability or wrongdoing with respect to the multi-year Ponzi scheme operated by Stanford and makes no admission in connection to any Stanford matter as part of the settlement. TD provided primarily correspondent banking services to Stanford International Bank Limited and maintains that it acted properly at all times. TD elected to settle the matter to avoid the distraction and uncertainty of continuing a long legal proceeding," the bank said in a statement. As a result of this settlement, TD will record a provision of approximately C$1.2B after tax in Q1.

12:01 EST Ready Capital falls -14.2% - Ready Capital is down -14.2%, or -$1.77 to $10.72.

12:00 EST Broadmark Realty Capital rises 12.9% - Broadmark Realty Capital is up 12.9%, or 54c to $4.69.

12:00 EST Fisker rises 30.2% - Fisker is up 30.2%, or $1.71 to $7.39.

11:45 EST Coinbase to suspend trading for Binance USD on March 13 - Coinbase said via Twitter, "We regularly monitor the assets on our exchange to ensure they meet our listing standards. Based on our most recent reviews, Coinbase will suspend trading for Binance USD (BUSD) on March 13, 2023, on or around 12pm ET...Trading will be suspended on Coinbase.com (Simple and Advanced Trade), Coinbase Pro, Coinbase Exchange, and Coinbase Prime. Your BUSD funds will remain accessible to you, and you will continue to have the ability to withdraw your funds at any time."

11:25 EST Syneos Health jumps following report on new effort to sell itself - Shares of Syneos Health (SYNH) are trading higher on Monday morning following a report by Reuters' David Carnevali and Anirban Sen saying the company is making a new effort to sell itself after a reduced backlog of contracts for providing clinical research to drug developers led to a 52% plunge in its shares over the past year, according to people familiar with the matter. Syneos has hired Bank of America Corp (BAC) in addition to Centerview as financial adviser as it embarks on a new round of talks with potential acquirers that may include industry peers and private equity firms, the sources said. Syneos' stock has gained over 7% to $40.54 in Monday morning trading following the report.Reference Link

11:16 EST Syneos Health trading resumes

11:07 EST Keysight Technologies signs MOU with Analog Devices to advance 6G tech design - Keysight Technologies (KEYS) announced that it has signed a memorandum of understanding with Analog Devices, Inc. (ADI) to advance 6G technology design and development. New 6G network capabilities will be based on existing and emerging technologies to enable new use cases and applications, the company said, adding that "Keysight and ADI will bring together high-performance solutions and expertise across a wide range of technology domains to realize the industry's evolving 6G vision. Under the MoU, the companies will collaborate to develop innovative solutions in technology areas critical to multiple facets of wireless network performance including energy efficiency as well as resilient and secure wireless connectivity."

10:39 EST Lionheart III Corp trading resumes

10:32 EST Integra Resources trading resumes

10:29 EST Lucy Scientific Discovery announces first commercial sale of psylocibin - Lucy Scientific Discovery announced that it has agreed to its first commercial sale to the prestigious Hadassah BrainLabs - Center for Psychedelics Research, Hadassah Medical Center, Hebrew University, Jerusalem, Israel. Hadassah BrainLabs was founded in 2013, as a National Knowledge Center for Research on Brain Disorders. Lucy has previously provided naturally-derived N.N-dimethyltryptamineto the Brain Lab and Biological Psychiatry Department at Hadassah-Hebrew University. Data resulting from studies using the provided material is anticipated to be published in the near future.

10:18 EST Verde Clean Fuels Inc trading halted, volatility trading pause

10:00 EST Coursera falls -9.1% - Coursera is down -9.1%, or -$1.10 to $11.04.

10:00 EST Tegna falls -23.6% - Tegna is down -23.6%, or -$5.16 to $16.68.

10:00 EST Broadmark Realty Capital rises 17.0% - Broadmark Realty Capital is up 17.0%, or 71c to $4.86.

09:59 EST Integra Resources, Millennial Precious Metals announce friendly at-market merger - Integra Resources (ITRG) and Millennial Precious Metals (MLPMF) announce that they have entered into an arm's length definitive agreement dated February 26 for an at-market merger, pursuant to which Integra and Millennial have agreed to combine their respective companiesby way of a court-approved plan of arrangement. Under the terms of the transaction, Millennial shareholders will receive 0.23 of a common share of Integra for each Millennial common share held. Existing shareholders of Integra and Millennial will own approximately 65% and 35%, respectively, of the outstanding Integra shares on the closing of the transaction, but prior to the completion of the equity financing contemplated. The exchange ratio implies consideration of C$0.18 per Millennial share based on the closing market price of the Integra shares on the TSX Venture Exchange on February 24. The consideration represents a no premium transaction. In connection with the transaction, the companies are pleased to announce concurrent equity financings for aggregate gross proceeds of C$35M, comprised of the brokered offering and non-brokered offering, the net proceeds of which are expected to be used by Integra, following completion of the transaction, to fund an updated Mineral Resource estimate and mine plan of operations at the DeLamar Project, the preparation of a Mineral Resource Estimate and Preliminary Economic Assessment on Millennial's Wildcat and Mountain View Projects, as well as on-going baseline work for additional permitting and exploration at the companies' respective projects, and for working capital and general corporate purposes. The companies are pleased to welcome Wheaton Precious Metals Corp. (WPM) as a new cornerstone investor, with Wheaton agreeing to invest an amount equal to up to 9.9% of the issued and outstanding Integra shares following the completion of the proposed Transaction and the conversion of the subscription receipts issuable to Wheaton and pursuant to the brokered offering. The equity participation of Wheaton in connection with the transaction provides significant project and transaction validation while also creating a partnership for future project financing. The equity financing also includes participation by Beedie Investments Ltd., an existing lender and shareholder of Integra.

09:47 EST Ready Capital falls -11.8% - Ready Capital is down -11.8%, or -$1.47 to $11.03.

09:47 EST Union Pacific rises 11.3% - Union Pacific is up 11.3%, or $21.84 to $214.56.

09:47 EST Broadmark Realty Capital rises 21.5% - Broadmark Realty Capital is up 21.5%, or 90c to $5.05.

09:37 EST Moolec Science SA trading resumes

09:32 EST Entravision named authorized sales partner of Meta Platforms in Mongolia - Entravision (EVC) announced that its Asia-based digital business unit has become the authorized sales partner in Mongolia of Meta (META).

09:30 EST Smith Micro announces contract termination by U.S.-based Tier 1 carrier customer - Smith Micro announced that the Company received written notice of contract termination from a U.S.-based Tier 1 carrier customer for the company's family safety solution, effective June 30. At the customer's election, the company remains obligated to deliver service under the agreement for a transition period of up to 180 days beyond June 30. The company is reviewing and expects to take appropriate action to reduce expenses associated with the affected customer agreement, and will reallocate certain resources to the company's multiple other Tier 1 U.S. carrier customers and to its customers outside of the U.S.

09:27 EST LTC Properties to transition or sell some properties in Brookdale portfolio - LTC Properties (LTC) announced that it plans to diversify its portfolio through the transition and possible sale of some of the properties in its Brookdale Senior Living (BKD) portfolio, following Brookdale's election not to exercise its lease renewal option. Brookdale is contractually obligated to pay rent on the portfolio of 35 assisted living communities across eight states through the end of the lease term on December 31. The portfolio represents 8.4% of pro forma annualized contractual cash rent, and 8.2% of pro forma annualized GAAP rent. LTC has funded approximately $7M in capital improvements in the properties over the last two years.

09:19 EST SciSparc signs agreement with Tikun Olam for supply of CBD-rich cannabis oil - SciSparc announced it has signed an agreement with Tikun Olam Cannbit Pharmaceuticals to supply CBD-rich oil from Cannbit strains by, to be used as part of its proprietary SCI-210 treatment, which is a combination of CBD and CannAmide. SCI-210 treatment will be used in the Company's clinical trial on children with autism spectrum disorder. The Trial will be conducted at the Soroka University Medical Center, led by Prof. Gal Meiri, head of the Soroka Preschool Psychiatry Unit. The Company has already secured approvals from the Israeli Ministry of Health as well as the Ethics Committee of the Soroka University Medical Center to conduct the Company's clinical trial. The Trial will evaluate the safety, tolerability and efficacy of SciSparc's drug candidate SCI-210, a proprietary combination of cannabidiol and CannAmide, in comparison to CBD monotherapy in children with ASD. The study design is a 20-week, randomized double-blind placebo-controlled with cross-over clinical trial on 60 children. The trial has three primary efficacy end points: the Aberrant Behavior Checklist-Community parent questionnaire; the Clinical Global Impressions-Improvement performed by a clinician; and the effective therapeutic dose.

09:16 EST Martinrea acquires assets of Effenco Developement, terms not disclosed - Martinrea International announced the acquisition of the assets of Montreal-based Effenco Development Inc., which were acquired in 2022. Effenco is a Green-Tech business that designs, manufactures and markets technologies for the electrification and connectivity of heavy duty vocational trucks. The Effenco Hybrid Electric solution augments the vehicle's powertrain and electrifies the onboard equipment utilizing a unique ultracapacitor-based technology. The technology creates value by helping to reduce greenhouse gas emissions, engine usage hours, fuel consumption, noise pollution, and related maintenance. Supporting Effenco's development activities is its real-time vehicle operations database, helping to ensure reliable performance for various applications and equipment. In addition, having collected over 1 million hours of real-world operating data, combined with its proprietary artificial intelligence algorithms, Effenco is well positioned to pursue its path in heavy-duty electrification.

09:13 EST Gevo finalizes hydrogen development services agreement with Zero6 - Gevo finalized a Hydrogen Development Services Agreement with Zero6 Energy for the development of a 20-megawatt hydrogen production facility in Lake Preston, South Dakota, using Cummins electrolyzer technology. The facility, known as the Dakota Renewable Hydrogen Project, will be an integral part of Gevo's Net-Zero 1 renewable hydrocarbon plant that is under development. Cummins will supply the project with an electrolyzer system comprised of four HyLYZER-1000 proton exchange membrane electrolyzers to produce hydrogen. Cummins' HyLYZER-1000 product is currently in operation at a similar facility in Becancour, Quebec, Canada. An electrolyzer splits water into oxygen and hydrogen. When powered by renewable electricity, the hydrogen produced is green and carbon free. This green hydrogen can be stored as a compressed gas or a liquid and used as an energy-dense, clean power source. Over 80% of the DRH hydrogen production capacity will be directly piped to the Gevo NZ1 plant to be used in the hydrocarbon refining process. The DRH will be located on the NZ1 plant property under a long-term lease agreement from Gevo.

09:12 EST Sony Select extends agreement with Kuke Music's Naxos China - Kuke Music Holding (KUKE) announced that Sony (SONY) Select has extended its agreement with the Company's subsidiary Naxos China, giving music enthusiasts and audiophiles instant access to the professional high-res classical music catalogues. Under the agreement, Naxos China will continue licensing its extensive library of high-resolution classical music catalogue to Sony Select, providing its users with an immersive and superior listening experience. He Yu, Chief Executive Officer of Kuke Music Holding Limited, commented, "We are pleased to continue our agreement with Sony Select, one of our long-term and most important licensing clients. This is another important strategic opportunity for us as we benefit from being aligned with industry leaders across the entire music ecosystem from creation to consumption. In the case of Sony Select, the platform has already established an impressive leadership position for its high-res app, which is viewed as a must-have for audiophiles and music enthusiasts. Both of our companies share in the commitment to providing superior quality audio tracks to our users. In addition, as Sony Select continues to expand its popular high-res music app in new online and offline usage scenarios, it can generate incremental revenue for Sony Select as well as its content providers, Naxos China included."

09:11 EST Antelope Enterprise Holdings appoints Zhang as new chairman - Antelope Enterprise Holdings, which operates KylinCloud, announced that on February 24, 2023, its Board of Directors appointed Weilai 'Will' Zhang, the Chief Executive Officer of the Company, as the Chairman of the Company's Board of Directors. Will Zhang joined the management team of the Company on January 5, 2023 and brings extensive entrepreneurial, venture capital and investment management experience to his new role. Since 2020, Zhang has acted as Chairman of Jinke Yulv Technology Ltd., an internet technology firm in China. Also, on February 24, 2023, Meishuang Huang, Chairperson of the Board, tendered her resignation. Huang's resignation was for personal reasons and not due to any disagreements with the Company or its management. In addition, the Company is announcing the results of its Special Meeting of Shareholders where the Company's shareholders approved the proposals to sell its legacy ceramic tile business, amend the Company's authorized share capital including the re-designation of ordinary shares to be Class A ordinary shares and Class B ordinary shares, and file an amended and restated memorandum and articles of association.

09:08 EST Xponential Fitness appoints Andrew Hagopian as chief legal officer - Xponential Fitness announced the appointment of Andrew Hagopian as the company's chief legal officer, effective March 1.

09:08 EST Steel Dynamics increases quarterly dividend 25% to 42.5c per share - Steel Dynamics announced that the company's board of directors declared a first quarter cash dividend of 42.5c per common share, a 25% increase over the company's 2022 quarterly rate. The dividend is payable to shareholders of record at the close of business on March 31, 2023 and is payable on or about April 14, 2023. "These actions reflect the Board's and senior leadership's confidence in the consistency and strength of our cash generation capabilities," said Mark D. Millett, Chairman, President, and Chief Executive Officer. "We have consistently grown our cash dividend to shareholders in alignment with our structural growth initiatives, maintaining a strong cash dividend growth profile. Based on our firm capital foundation and consistent cash generation, we have the ability to execute significant organic and transactional strategic growth initiatives, while sustaining strong shareholder distributions and remaining committed to maintaining our investment grade credit ratings."

09:06 EST GeoVax announces presentation of results from clinical study of HIV therapy - GeoVax Labs announced the presentation of results from a clinical study of a combinational HIV therapy that included GeoVax's HIV vaccine candidate, MVA62B. The data were presented at the Conference on Retroviruses and Opportunistic Infections held February 19-22, 2023, in Seattle, Washington. The data were generated, in a clinical trial led by researchers at the University of California, San Francisco, to develop a combinational therapy aimed at reducing or eliminating viral replication in the absence of antiviral medications in HIV-positive individuals. The primary objectives of the proof-of-concept trial were to assess the safety and tolerability of the combinational therapy and to determine the viral load "set-point" during antiviral treatment interruption. Secondary objectives were to assess immune responses and changes in viral reservoir status. The clinical trial was led by Steven Deeks, M.D. of UCSF, a world leader in therapeutic approaches to HIV infections, and was one of the most comprehensive tests to date for the ability of synergistic approaches to control HIV infection. The studies were conducted with funding from amfAR, The Foundation for AIDS Research.

09:03 EST Dan Bongino launches 'The Dan Bongino Show' on Rumble - Rumble announced that Dan Bongino will relaunch "The Dan Bongino Show" as a live premiere on Rumble, broadcasting every weekday at 11 a.m. Eastern Time. This new format will allow viewers to interact in real time and access the content on-demand immediately following the show .Currently, "The Dan Bongino Show" has 2.59 million followers-the most of any channel on Rumble.

09:02 EST Pioneer Natural says 'not contemplating a significant business combination' - On Friday night, after Bloomberg reported based on its sources that Pioneer Natural Resources (PXD) was considering an acquisition of Range Resources (RRC), Pioneer Natural Resources issued a company update, stating: "Pioneer Natural Resources Company announced today that the company is not contemplating a significant business combination or other acquisition transaction." In Monday pre-market trading, Range Resources shares are down 8% to $26.00 while Pioneer shares are up $4.33, or 2%, to $200.90.

09:01 EST Cenntro Electric starts production of LS400, Metro electric trucks in U.S. - Cenntro Electric announced the start of production of its LS400 and Metro electric commercial trucks at the company's recently expanded assembly facility in Howell, New Jersey. Additionally, the company is also announcing the completion of its new assembly facility in Jacksonville, Florida. Production of the LS400 and Metro electric commercial vehicles in the Howell Assembly Facility is underway. Vehicles assembled at the Howell facility are predominantly for the Northeastern region of the United States. Cenntro also announced the completion of the build-out of Jacksonville Assembly Facility and is awaiting parts to begin the production of the LS400 and Metro product lines.

08:52 EST Amdocs selected by Melon Digital to launch MVNE platform - Amdocs announced that Melon Digital, a new digitally-led mobile virtual network enabler based in South Africa, has selected Amdocs' Digital Brands Suite as a Service to provide customer care and monetization capabilities in a SaaS-based solution powered by Amazon Web Services.

08:50 EST Brightline Interactive signs CRADA with U.S. NSWCDD - Brightline Interactive announced the signing of a Cooperative Research and Development Agreement with the United States Naval Surface Warfare Center, Dahlgren Division for the adaptation of immersive technologies. Brightline Interactive provides system architectures and integrated technology components, such as simulator systems, necessary to deploy complex, end-to-end Immersive Hyperscale Environments. These are high performance, cloud-centric, computing platforms that incorporate artificial intelligence elements enabling high-level, cost-effective simulations between the real and virtual worlds.

08:47 EST Rhythm Pharmaceuticals acquires Xinvento for upfront payment of $5M - Rhythm Pharmaceuticals announced that Rhythm's Netherlands subsidiary, Rhythm Pharmaceuticals Netherlands B.V. acquired Xinvento B.V., a Netherlands-based biotech company focused on developing therapies for congenital hyperinsulinism. CHI is a rare genetic disease in which cells secrete excess insulin, causing hypoglycemia, which can result in serious health outcomes including seizures, coma, permanent brain damage and death. Xinvento was founded in 2021 by Claudine van der Sande, an experienced biopharmaceutical leader who previously held positions at Roche and Sanofi, and whose first-hand experience as a caregiver to her son living with CHI inspired her mission to seek a more effective treatment for CHI patients. Ms. van der Sande partnered with Dr. Piet Wigerinck, a medicinal chemist who served as chief scientific officer of Galapagos for 10 years, to lead the scientific effort. Xinvento is developing novel investigational therapeutic candidates designed to improve the care of patients with CHI. Following the closing of this acquisition, Ms. van der Sande, Founder and CEO of Xinvento, will join Rhythm as Vice President, Head of CHI program, and will provide her deep subject matter expertise to the advancement of the CHI program. According to the terms of the acquisition agreement, Rhythm B.V. will purchase 100 percent of Xinvento's fully-diluted equity for an upfront payment of $5 million with an additional payment of up to $6 million in preclinical development milestones and up to an additional $50 million payable upon certain U.S. or EU regulatory approvals. Rhythm B.V. will also pay up to an additional $150 million in certain commercial net sales milestones related to the lead candidate or a second molecule, in the event a second molecule is selected, developed and approved.

08:45 EST Porch Group's V12 rebrands Porch Group Media - V12, subsidiary of Porch Group, announced its rebrand to Porch Group Media, reflecting its transformation to a provider of proprietary first-party audiences and managed media network solutions offered through the Porch Group Media Network, the first media network to target movers and homeowners with insights into more than 90% of all U.S. homebuyers per year. "Dozens of brands are utilizing our custom audiences and media and advertising packages across channels including CTV, email, direct mail, digital and social. These clients have seen tremendous results by being able to better target the right consumers for acquisition and retention and see measurable results with our suite of attribution tools," said Kym Vance, Porch Group Media's CRO. "We are excited for this next chapter of growth and to be able to offer brands such a robust and unique set of tools to help them succeed."

08:42 EST Imunon, Break Through Cancer commence enrollment in Phase 1/2 study - IMUNON announces the commencement of patient enrollment in a collaboration to evaluate IMUNON's IMNN-001 in combination with bevacizumab in patients with advanced ovarian cancer. The trial is now active at the University of Texas MD Anderson Cancer Center. IMNN-001 is a DNA-based interleukin-12 immunotherapy currently in Phase 2 clinical development for the localized treatment of advanced ovarian cancer. This new Phase 1/2 study, titled "A Phase I/II Study Evaluating the Effect of IMNN-001 on Minimal Residual Disease as determined by Second Look Laparoscopy when Administered in Combination with Bevacizumab and Neoadjuvant Chemotherapy in Subjects Newly Diagnosed with Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer" is expected to enroll 50 patients with Stage III/IV advanced ovarian cancer and is being led by principal investigator Amir Jazaeri, M.D., Professor of Gynecologic Oncology and Reproductive Medicine at MD Anderson. Patients undergoing frontline neoadjuvant therapy will be randomized 1:1 to receive standard chemotherapy vs. chemotherapy plus IMNN-001. The primary endpoint is detection of minimal residual disease by second look laparoscopy and the secondary endpoint is progression-free survival. Initial SLL data are expected within one year from the completion of enrollment and final PFS data are expected approximately three years from the completion of enrollment. This trial will also include a wealth of translational endpoints aimed at understanding the clonal evolution and immunogenomic features of the MRD phase of ovarian cancer that is currently undetectable by imaging or tumor markers.

08:41 EST Verses Technologies announces convertible debenture financing up to C$5M - VERSES Technologies announced a non-brokered private placement of unsecured convertible debentures units of the Company at a price of C$1,000 Unit for gross proceeds of up to C$5,000,000. Each Unit will consist of: C$1,000 principal amount unsecured convertible debentures of the Issuer; and (ii) 350 detachable warrants to purchase Class A Subordinate Voting shares of the Issuer. Each Convertible Debenture will mature on the date that is 12 months from the date of issuance of the Convertible Debenture. On the Maturity Date, the outstanding principal amount of the Convertible Debentures shall be repaid in cash. The Principal Amount shall be convertible, for no additional consideration, upon the closing of an Equity Financing into such number of Equity Securities as is equal to the Principal Amount divided by the Equity Financing Price.

08:40 EST Tegna extends outside date for merger with Standard General to May 22 - On February 22 TEGNA and Standard General announced that TEGNA and an affiliate of Standard General entered into a definitive agreement under which TEGNA will be acquired by the Standard General affiliate for $24 per share in cash. TEGNA stockholders voted to approve the transaction at the special meeting of stockholders held on May 17. On February 21 , TEGNA elected, pursuant to the terms of the Merger Agreement, to extend the Outside Date from 5:00 p.m. Eastern time on February 22 to 5:00 p.m. Eastern time on May 22, . All waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, applicable to the Merger and related transactions have expired. The closing of the transaction remains subject to the approval of the Federal Communications Commission and customary closing conditions. On February 24 , the FCC issued a hearing designation order with respect to the transaction. TEGNA is currently evaluating its options.

08:38 EST BioAtla president Scott Smith departs - BioAtla (BCAB) announced that its President, Scott Smith, will be leaving the Company to pursue a new opportunity as CEO at Viatris (VTRS). Scott will continue his relationship with BioAtla by serving as a Board of Directors member for the Company.

08:37 EST Recon Technology announces progress on development of new electric pump - Recon Technology announced that a mainland China variable interest entity's subsidiary, Nanjing Recon Technology, has achieved preliminary progress on the research and development of a new energy-efficient electric pump that is being conducted at some oilfield sites in China. Through 18 months of on-site testing, the lab data shows the R&D work has achieved initial experimental results. Electric pumps in oilfield use a lot of energy, signifying great market potential for energy-efficient upgrading. Direct-drive permanent magnet synchronous motor are used as electric pumps in the oilfield water injection process, which are significantly more efficient than the conventional three-drive motors. Shenping Yin, Founder and CEO of Recon commented: "Each machine is expected to help save electricity expenses by RMB100,000 yuan per year. The oilfield company we launched the R&D project with has about 1,500 water pumps and is highly motivated to upgrade to more energy efficient pumps... We expect to set the price of our new electric pump at hundreds of thousands of RMB per unit and we are also in talks with some prospective clients and anticipate receiving about 20 to 30 orders in 2023."

08:35 EST Silicom secures design win for one of its Edge Networking products - Silicom announced that it has secured another Design Win for one of its pioneering Edge Networking products. The customer, a leading Secure Access Service Edge, SASE, vendor, has already placed an initial deployment order that will be delivered by Silicom during the first half of 2023. In addition, Silicom and the customer are working together on a wireless Edge Networking solution that will support additional use cases, further expanding the business potential of the relationship. "This strategic win, added to our growing roster of SASE and other Edge related design wins, clearly demonstrates that our Edge Networking momentum is building far beyond the SD-WAN space," commented Liron Eizenman, Silicom's CEO. "The 'package' of advantages we offer, including the market's broadest portfolio of Edge Networking offerings, attractive price points, exceptional customization capabilities and our strong relationship with Intel, is proving to be compelling for all types of market players: not just solution vendors, but also telcos, service providers and more.

08:34 EST 180 Life Sciences announces presentation at the Gordon Conference - 180 Life Sciences announced that Professor Jagdeep Nanchahal has been selected to present at the Gordon Research Conference on "Physiological and Disease Relevance and Underlying Molecular Properties of Collagens", at Colby-Sawyer College, New London, New Hampshire, from July 9 - 14, 2023. Jagdeep Nanchahal, Professor of Hand, Plastic and Reconstructive Surgery at the University of Oxford and chairman of the clinical advisory board of 180 Life Sciences will be presenting his findings on Dupuytren's disease. His team has been the leaders in the modern application of molecular and single cell techniques to describe the cellular composition of early-stage Dupuytren's nodules. This detailed analysis has unraveled the signaling pathways that drive the progression of the disease. They identified tumor necrosis factor as a potential therapeutic target, followed this up by a phase 2a trial to identify the optimal dose and formulation of adalimumab and then performed an original, very challenging phase 2b clinical trial. We believe the trial was successful as the trial succeeded in achieving its primary and secondary endpoints with statistical significance.

08:33 EST Agile Therapeutics granted 180-day extension to regain Nasdaq compliance - Agile Therapeutics announced that it has received written notification from the Listing Qualifications Department of the Nasdaq Stock Market granting the Company's request for a 180-day extension to regain compliance under Nasdaq Listing Rule 5550(a)(2). The Company now has until August 14, 2023 to meet the requirement. The extension notice from Nasdaq has no immediate effect on the listing or trading of the Company's shares, which will continue to trade on the Nasdaq Capital Market under the symbol "AGRX." If at any time prior to the Compliance Date, the bid price of the Company's common stock closes at, or above, $1.00 per share for a minimum of ten consecutive business days, the Nasdaq Listing staff will provide the Company with written confirmation of compliance and the matter will be closed. On August 15, 2022, the Company was notified by the Nasdaq Listing Qualifications Department of Nasdaq of its failure to maintain a minimum bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The Company originally had 180 calendar days, or until February 13, 2023 to regain compliance. The Company will continue to monitor the bid price of its common stock. If the Company does not meet the minimum bid price requirement prior to the Compliance Date, the Nasdaq Listing Qualifications Department will notify the Company the Company that its common stock will be subject to delisting. At such time, the Company may appeal the delisting determination to the Nasdaq Hearings Panel. There can be no assurance that if the Company does appeal a subsequent delisting determination, that such appeal will be successful.

08:32 EST Herborium Group to join Faire B2B Wholesale Marketplace - Herborium Group announced that is joining Faire B2B Wholesale Marketplace to expend its domestic and internal market access and further grow its brands.

08:29 EST Aurora Technology, DIH enter definitive business combination agreement - DIH Holding US and Aurora Technology Acquisition announced they have entered into a definitive business combination agreement that will result in DIH becoming publicly listed. Upon the closing of the transaction the SPAC will domesticate from the Cayman Islands to Delaware. The combined company will be named DIH Holding US, Inc. and its securities are expected to be listed on Nasdaq. Management Commentary: Zachary Wang, CEO and Chairman of ATAK's board of directors, commented, "DIH has built an advanced healthcare technology platform that serves as a leading provider of smart technology in the human rehabilitation and performance industry. We launched Aurora Technology Acquisition Corp, to identify and collaborate with innovative companies that have the potential for multi-national expansion. Built by Asian-American healthcare experts with decades of experience managing global healthcare operations, DIH is an ideal match for our target profile." Transaction Overview: The estimated pro forma enterprise value of the combined company is $321.9M, including an anticipated $20.0M of DIH net debt at the time of closing, and $58.3M of cash held in the trust account of ATAK, subject to redemptions. In addition, equity holders of DIH shall be entitled to receive up to $60.0 million of common shares of the combined company depending on certain stock price-based thresholds being achieved within five years from the closing of the transaction. The transaction, which has been unanimously approved by the boards of directors of DIH and ATAK, is subject to approval by the stockholders of DIH and ATAK, respectively, and other customary closing conditions.

08:27 EST Enphase Energy expands IQ8 microinveter deployments in Pennsylvania - Enphase Energy announced today that installers of Enphase products in Pennsylvania have seen growing deployments of Enphase Energy Systems powered by IQ8TM Microinverters.

08:26 EST Surge Copper announces assay results from Berg Property - Surge Copper announced complete assay results for 4 holes from the Bergette target on the Company's Berg Property in British Columbia. These are the first holes drilled by Surge at the historic Bergette target and, combined with new geologic and geophysical work, are helping to demonstrate the potential of the large Bergette system. Highlights: Hole BGT22-01 returned 143 metres grading 0.29% copper equivalent from 3 metres depth, including 55 metres of 0.42% copper equivalent and 18 metres of 0.68% copper equivalent; Hole BGT22-02 returned 176 metres grading 0.29% copper equivalent from 8 metres depth, including 154 metres grading 0.31% copper equivalanet and 16 metres grading 0.70% copper equivalent; Hole BGT22-02 is the longest mineralized intercept encountered at the Bergette target to date, and mineralization correlates with moderate induced polarization chargeabilty values and strong magnetic geophysical response, providing good targeting critera for additional exploration; Results for 6 drill holes from the Sibola and Sylvia targets are pending/ Leif Nilsson, Chief Executive Officer, commented: "The Bergette target is one of the more advanced exploration targets in this district, with some shallow historical drill intercepts, and extensive soil sampling across the target area. Surge has acquired new exploration data covering the target area, including airborne ZTEM and magnetics, ground-based IP, and surface sampling, and during the 2022 regional exploration program, completed four holes from three locations across the target area, each separated by over a kilometre. These results, consistent with some of the historical drill results, demonstrate some compelling grades close to surface, and will provide us with better constraining information to improve targeting. The overall size of geophysical and geochemical anomalies across the target area, and proximity to infrastructure underscore the quality of Bergette as an exploration target."

08:25 EST Integrated Wellness, Refreshing USA file form S-4 Registration Statement - Integrated Wellness Acquisition and Refreshing USA, an independent automated and unattended retailer, announced the filing of a registration statement on Form S-4 by IWAC Holdings, which contains a preliminary proxy statement/prospectus, with the U.S. Securities and Exchange Commission in connection with their recently announced proposed business combination. On February 10, 2023, Integrated Wellness and Refreshing announced their entry into a definitive agreement and plan of merger relating to a business combination that would result in Refreshing becoming a public company upon the closing of the proposed transaction. The Transaction is expected to close in the first half of 2023 and is subject to approval by Integrated Wellness' shareholders, regulatory approval, and other customary closing conditions.

08:23 EST Shoals Technologies appoints Jeffery Tolnar as interim CEO - Shoals Technologies announced the appointment of Jeffery Tolnar, President, to Interim Chief Executive Officer upon the departure of Chief Executive Officer Jason Whitaker, as previously communicated. Tolnar will succeed Mr. Whitaker in an interim role. Following completion of an extensive search and vetting process, Shoals' Board of Directors intends to identify a permanent Chief Executive Officer. Tolnar was appointed President of Shoals after successfully launching the Company's eMobility business unit. As President and Interim CEO, Mr. Tolnar will continue to be responsible for leading the Company's growth, operational excellence, technology development and product innovation.

08:22 EST Innoviz Technologies expands German footprint with new Munich office - Innoviz Technologies announced it has officially opened a new office in Munich, Germany. The new office offers proximity to key customers and partners for greater collaboration and execution, as well as for new business opportunities. The new Munich office inhabits sales and engineering staff and has a place for hosting meetings and demos. Innoviz plans to hire locally as its project portfolio is likely to continue to ramp up. "We are expanding Innoviz's operations globally, and a Munich office is an important move for us as we execute on our design wins with key customers such as Volkswagen and BMW. Germany is one of the leading automotive markets and it is a top priority for us to maintain good relationships with our customers and continue to grow our business in the region" said Innoviz CEO and Co-Founder Omer Keilaf.

08:17 EST Triumph Group announces proposed private offering of senior secured notes - Triumph Group announced that it has commenced a refinancing of its outstanding secured bonds, through an offering of $1.2 billion aggregate principal amount of senior secured first lien notes due in 2028. The Notes will be guaranteed by the same subsidiaries that guaranty Triumph's 7.750% Senior Notes due 2025, and will be secured by first-priority liens on substantially all of the Company's and the Guarantors' assets. Triumph intends to use the net proceeds from the Notes Offering to redeem or otherwise acquire all of its outstanding 8.875% Senior Secured First Lien Notes due 2024 and 6.250% Senior Secured Notes due 2024. Subject to the successful completion of the Notes Offering, the Company intends to redeem all of the outstanding Existing First Lien Notes.

08:15 EST Otis Worldwide appoints Sally Loh as President, Otis China - Otis Worldwide announces the appointment of Sally Loh as President, Otis China, reporting directly to Otis Chair, CEO & President, Judy Marks. Effective March 1, Loh will succeed Perry Zheng, who will return to Otis World Headquarters in the newly created role of Executive Vice President, Chief Product, Delivery and Customer Officer. Loh has been with Otis for 23 years, working closely alongside Zheng for several years. She was most recently Chief Operating Officer responsible for day-to-day business operations of Otis China.

08:14 EST Leidos selects Thomas Bell as incoming CEO - Leidos (LDOS) announced the appointment of Thomas Bell as Chief Executive Officer, expected to be effective May 3, 2023. Bell, current President - Defense Rolls-Royce (RYCEY); Chairman & Chief Executive Officer, Rolls-Royce North America, will succeed current Chairman and CEO, Roger Krone, who has served in the role since 2014. Krone will retire as Chairman at the time of the Leidos 2023 annual meeting of stockholders, and CEO when Bell's appointment becomes effective. The Board expects to appoint Robert Shapard independent, non-executive chair after the 2023 annual meeting of stockholders and will also nominate Bell to the Board. To facilitate a seamless leadership transition, Krone will continue as a fully employed advisor through July of this year.

08:12 EST Apexigen announces review of strategic alternatives, 55% workforce reduction - Apexigen engaged Ladenburg Thalmann & Co. to evaluate strategic alternatives for the Company with the goal of maximizing stockholder value. As part of this process, the Company will explore the potential for an acquisition, company sale, merger, divestiture of assets, licensing, or other strategic transactions. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms. The Company does not expect to disclose or provide an update concerning developments related to this process until the Company enters into definitive agreements or arrangements with respect to a transaction or otherwise determines that other disclosure is necessary or appropriate. Apexigen will also implement a corporate restructuring to extend its cash runway as it reviews and explores strategic alternatives. As part of the restructuring, Apexigen plans to reduce its workforce by 55%.

08:11 EST Avantax announces preliminary results of tender offer - Avantax announced the preliminary results of its modified "Dutch auction" tender offer for up to $250 million of its common stock at a price per share not less than $27.00 and not more than $31.00, which expired at 12:00 midnight, New York City time, at the end of the day on February 24, 2023. In accordance with the terms and conditions of the tender offer and based on the preliminary count by the depositary, the Company expects to repurchase a total of 8,333,333 shares of Company common stock through the tender offer at a price of $30.00 per share, for a total cost of $249,999,990, excluding fees and expenses. Based on the preliminary count by the depositary for the tender offer, a total of 8,876,199 shares of Company common stock were validly tendered and not validly withdrawn at or below the price of $30.00 per share, including 4,741,023 shares that were tendered through notice of guaranteed delivery. Because the tender offer was oversubscribed, the Company expects to purchase approximately 93.9% of the shares of stockholders who submitted auction tenders at a price of $30.00 or less per share and purchase price tenders. The total of 8,333,333 shares that the Company expects to accept for repurchase represents approximately 17.4% of the Company's total outstanding shares of common stock as of February 24, 2023. The Company does not expect to purchase any shares from stockholders who submitted auction tenders at a price in excess of $30.00 per share. As previously disclosed, the Company expects to fund the purchase of shares in the tender offer with cash on hand and borrowings under its delayed draw term loan facility.

08:09 EST AT&T and ServiceNow announce global telco solution - AT&T (T) and ServiceNow (NOW) announced a global telecom product to help communications service providers (CSPs) manage 5G and fiber network inventory. AT&T provided strategic design and technical guidance for the development of ServiceNow Telecom Network Inventory, which is built on the ServiceNow Platform and available for telcos globally today. The current approach to managing network inventory is complex and challenging. CSPs need a consolidated view of their networks and a consistent workflow to connect and action on data. Telecom Network Inventory helps to address these needs by providing a single platform that connects systems to maximize network investments, manage orders, improve customer service experiences, and enable business agility. AT&T plans to deploy the platform soon. "Working with ServiceNow to develop Telecom Network Inventory was a great collaboration to create a tool that could help us address an industry-wide challenge," said Jon Summers, senior vice president of information technology and chief information officer, AT&T. "As we approach our internal deployment, we also look forward to seeing how other operators around the globe might take advantage of it."

08:08 EST Actinium Pharmaceuticals to discuss results from Phase 3 trial of Iomab-B - Sandesh Seth, Actinium's Chairman and CEO, said, "We are honored that Dr. Giralt, who is instrumental in advancing the field of bone marrow transplant, will present the SIERRA data and frame how Iomab-B can address the unmet need for the majority of r/r AML patients who are not transplantable today. We are excited to move ahead with the BLA filing of Iomab-B in 2H:2023 following the highly positive, full results from the SIERRA trial which clearly established Iomab-B's ability to provide unprecedented access to a BMT to patients who currently not transplantable and to meaningfully improve outcomes. Additionally, we are enthused by the other consequential milestones we intend to achieve in 2023 including moving Actimab-A into late-stage development following our recent CRADA with the NCI, additional data and important studies with Iomab-ACT, the Early Access Program for Iomab-B and progress with our earlier stage solid tumor programs. Our current balance sheet of approximately $100 million is expected to fund operations through 2025 and will allow us to continue to create value from these important milestones and provide clarity on how Actinium could radically alter the treatment of r/r AML with Iomab-B and Actimab-A and dramatically improve outcomes".

08:07 EST Avidity Biosciences advances RNA programs, expands into new therapeutic areas - Avidity Biosciences announced the advancement and expansion of its internal discovery pipeline with the addition of new research and development candidates to treat conditions in skeletal muscle and cardiology. The preclinical programs have been engineered using Avidity's proprietary AOC platform technology. "With the revolutionary advancement of demonstrating the first-ever successful targeted delivery of RNA into muscle, we are keen to broaden the utility of the AOC platform. We are now pursuing new programs in skeletal muscle and cardiology and believe that there are many more opportunities where AOCs can address debilitating diseases previously unreachable with existing RNA therapies," said Sarah Boyce, president and chief executive officer at Avidity. "We look forward to advancing our own internal research and development programs as well as partnering with collaborators as we work to fulfill our mission to profoundly improve people's lives by delivering a new class of RNA therapeutics." Avidity continues to advance its three distinct rare disease Phase 1/2 programs in the clinic: AOC 1001 for myotonic dystrophy type 1, AOC 1020 for the treatment of facioscapulohumeral muscular dystrophy and AOC 1044 for the treatment of Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping. Avidity has decided not to pursue research and development programs in muscle atrophy and Pompe disease at this time.

08:06 EST Lucira Health announces FDA authorization of COVID-19 & Flu Home Test - Lucira Health announced that the U.S. Food and Drug Administration granted emergency use authorization for its Lucira COVID-19 & Flu Home Test for over the counter use at home and other non-laboratory sites. The Lucira COVID-19 & Flu Home Test is a molecular test that demonstrated similar performance for COVID-19 and Influenza A and B compared to highly sensitive lab-based PCR tests in clinical trials. Lucira's COVID-19 & Flu Home Test represents a breakthrough in diagnostic testing as the first at-home combination COVID-19 and Flu test, and as the first Flu test for OTC use at home in the United States in history. Until today, American consumers have never before been able to self-diagnose Flu at home. The easy-to-use, all-in-one combination test delivers results in 30 minutes or less from one shallow nasal swab.

08:05 EST Windtree Therapeutics to present istaroxime data - Windtree Therapeutics is targeting cardiogenic shock as a potential indication for its drug candidate, istaroxime. The Company announced that its abstract entitled "Safety and Efficacy of Istaroxime 1.0 and 1.5 microgram/kg/min for Patients with Pre Cardiogenic Shock" has been accepted for presentation at the Technology and Heart Failure Therapeutics Conference being held on March 20-22, 2023 in Boston, MA. The data are from the Company's SEISMiC Phase 2 study, an international, randomized, double blind, placebo-controlled study that enrolled 60 patients with Society for Cardiovascular Angiography & Interventions Stage B early cardiogenic shock due to severe heart failure with SBP between 75-90 mmHg. Two target doses of istaroxime were studied compared to placebo. The primary endpoint was the difference in SBP area under the curve over six hours after initiating the infusion. As previously reported, the study met its primary endpoint in SBP profile over six hours, with the pooled istaroxime treated group performing significantly better compared to the control group. The improvement persisted through the 24-hour SBP profile measurement, which was also statistically significant. More detailed analysis of the trial data by dose will be presented at this meeting.

08:03 EST Integra Resources trading halted, news pending

08:03 EST Evofem announces FDA Orange Book listing of two additional U.S. patents - Evofem Biosciences announced that two additional U.S. patents which cover Phexxi and its labeled indication are now listed in the U.S. Food and Drug Administration publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. "The Orange Book listing of these two patents covering Phexxi's composition of matter and its method of use in contraception is an important step in further strengthening our patent portfolio," said Evofem Biosciences CEO Saundra Pelletier. "We plan to further expand our intellectual property estate in the U.S. and overseas as we continue to iterate our vaginal pH modulator platform and seek entry into global markets." The newly listed U.S. Patent No. 11,337,989 covers contraception using the L-Lactic Acid Phexxi formulation. The '989 patent was issued by the U.S. Patent and Trademark Office on May 24, 2022 and is expected to expire in March 2033. The newly listed U.S. Patent No. 11,439,610covers compositions containing L-Lactic Acid, including the Phexxi formulation. The '610 patent was issued by the USPTO on September 13, 2022 and is expected to expire in March 2033.

08:01 EST INTEGRA RES CORP COM NEW trading halted, news pending

07:53 EST Viatris annouces appointment of Smith as CEO - Viatris (VTRS) announced that as it prepares to enter Phase 2 of its previously announced strategic plan in 2024, Scott Smith has been appointed by its Board of Directors to lead the execution of that plan as Viatris' new Chief Executive Officer, effective April 1, 2023. In the interim, current CEO Michael Goettler will be working closely with Smith to support a smooth transition and will then depart as CEO and as a member of the board. Smith has been a member of the Viatris Board since December 2022 and is a deeply knowledgeable senior global biotechnology and pharmaceutical executive with more than 35 years of experience. Most recently, he served as President of BioAtla, Inc. (BCAB)

07:48 EST Gilat Satellite announces availability of SkyEdge IV Taurus-M - Gilat Satellite Networks announced the launch of SkyEdge IV Taurus-M, which is a new satellite modem product specifically designed for military and government markets. The SkyEdge IV Taurus-M modem is backward compatible to SkyEdge II-c and, as such, protects past investments of customers whom have already adopted Gilat's leading satellite network platform.

07:47 EST Columbia Care, Cresco Labs extend acquisition closing timeline to June 30 - Columbia Care (CCHWF) announced that it has mutually agreed with Cresco Labs (CRLBF) to extend the outside date to complete the proposed acquisition by Cresco Labs of Columbia Care from March 31 to June 30. The extension will allow the companies additional time to finalize divestiture agreements and obtain the regulatory approvals required to close. Columbia said in a statement. "We continue to make meaningful progress on the remaining divestitures and look forward to making those announcements. We are driving operational efficiencies, enhancing market-level scale to offset pricing pressure, and demonstrating leadership in several of the fastest growing markets in the industry, such as New Jersey, Virginia and West Virginia. These efforts will enable the combined company to leverage Columbia Care's leading retail footprint while maintaining Cresco's wholesale leadership. We are grateful to the entire Columbia Care team for their ongoing commitment to driving our business forward in advance of the merger," said Nicholas Vita, CEO of Columbia Care.

07:42 EST Microbix Biosystems announces issuance of stock options - Microbix Biosystems announces the issuance of stock options under its shareholder-approved 2018 stock option plan, as part of its compensation programs to incentivize and retain its board of directors, executives, and managers. In consultation with management, Microbix's Board of Directors has approved the issuance of 2,815,000 options in accordance with the terms of the Stock Option Plan. The approved options are exercisable at a price of $0.37 per share, as determined by the closing price of the TSX on 23 February, 2023. Each option will vest and be exercisable after three years and have a total life of five years. The stock option grants form part of the total remuneration package for the recipients and are subject to TSX approval.

07:41 EST Mayfair Gold announces results from Fenn-Gib drill program - Mayfair Gold announces further results from the higher-grade Footwall Zone located approximately 100 meters to the north of the Fenn-Gib gold deposit. Mayfair's 100% controlled Fenn-Gib Project, located in the Timmins region of Northeast Ontario, hosts a NI 43-101 open-pit-constrained Indicated Resource of 3.06 million ounces and an Inferred Resource of 0.31M ounces, with disseminated gold mineralization striking east-west on the Pipestone Fault over more than 1.25 kilometers and up to 300m wide at the west end. Mayfair Gold President and CEO, Patrick Evans, commented: "Ongoing drilling in 2023 has extended the northeastern strike of the Footwall Zone mineralized structure by approximately 200m in six drill holes. The Footwall Zone mineralization now strikes for approximately 400m, outcrops at surface, has been intersected vertically down to approximately 500m below surface, and remains open in all directions. Drilling continues to confirm the higher-grade gold mineralization, and two drill rigs are active to determine the structure and tonnage potential of the Footwall Zone." Highlight reported drill result includes: FG23-300 intersected 2.05 grams/tonne gold over 16.2m, including 3.72 g/t Au over 6.2m. In addition to gold assay results from hole FG23-300, assays are pending for Footwall Zone holes FG23- 304, 309, 311, 313 and 314 that have all intersected multiple altered and mineralized zones.

07:37 EST Silver Tiger Metals announces drill results from Sulphide Zone - Silver Tiger Metals has intersected 2,668.8 g/t total silver equivalent over 2.8 meters in the Sulphide Zone in Drill Hole ET-22-440 from 421.7 meters to 424.5 meters, consisting of 1,986.3 g/t silver, 0.21 g/t gold, 4.02% copper, 3.94% lead and 5.64% zinc within 36.4 meters grading 457.2 g/t total silver equivalent from 397.9 meters to 434.3 meters consisting of 314.6 g/t silver, 0.25 g/t gold, 0.58% copper, 0.90% lead and 1.40% zinc in the Sulphide Zone. Highlights from the on-going drilling program include the following: Hole ET-22-441: 2.0 meters grading 2,656.0 g/t total silver equivalent from 432.5 meters to 434.5 meters, consisting of 1,255.7 g/t silver, 0.20 g/t gold, 2.02% copper, 12.67% lead and 26.87% zinc within 20.0 meters grading 845.1 g/t total silver equivalent from 415.3 meters to 435.3 meters consisting of 369.0 g/t silver, 0.35 g/t gold, 0.85% copper, 4.11% lead and 8.15% zinc in the Sulphide Zone. Hole ET-22-442: 1.2 meters grading 2,978.1 g/t total silver equivalent from 378.2 meters to 379.4 meters, consisting of 2,614.0 g/t silver, 0.24 g/t gold, 2.67% copper, 1.82% lead and 1.38% zinc within 22.1 meters grading 263.5 g/t total silver equivalent from 370.0 meters to 392.1 meters consisting of 221.7 g/t silver, 0.08 g/t gold, 0.21% copper, 0.28% lead and 0.28% zinc in the Sulphide Zone. Hole ET-22-443: 3.3 meters grading 1,239.0 g/t total silver equivalent from 441.0 meters to 444.3 meters, consisting of 633.8 g/t silver, 0.19 g/t gold, 1.04% copper, 4.80% lead and 11.38% zinc within 37.8 meters grading 388.8 g/t total silver equivalent from 418.6 meters to 456.4 meters consisting of 171.7 g/t silver, 0.19 g/t gold, 0.39% copper, 1.85% lead and 3.67% zinc in the Sulphide Zone. Silver Tiger's CEO, Glenn Jessome, stated, "These drill results targeted the newly discovered Sulphide Zone along strike to the North and have intercepted wide, high-grade mineralization." Mr. Jessome further stated: "The Sulphide Zone dimensions are now in excess of 200 meters along strike, approximately 75 meters across strike with apparent widths approaching 35 meters, and open in all directions."

07:36 EST Signal Gold receives $16M from initial drawdown of Nebari credit facility - Signal Gold received the initial drawdown of $16.0 million of its previously announced $21.0 million credit facility with Nebari Gold Fund 1 LP, Nebari Natural Resources Credit Fund I LP, and Nebari Natural Resources Credit Fund II LP. The Credit Facility also provides for a second tranche of $5.0 million, at the election of the Company, subject to satisfaction of certain conditions precedent. The Credit Facility has a maturity date of two years from the initial draw with the option to extend up to another 12 months and is expected to be repaid from the proceeds of a project finance facility for Goldboro which the Company is targeting to occur later in 2023. The proceeds of $16.0 million from Tranche 1 will be used to progress critical pre-development activities for the Goldboro Project and the repayment of the existing $8.0 million senior secured facility with Auramet International LLC. Key activities include detailed engineering to support industrial approval permits, an updated Feasibility Study to include an updated Mineral Resource Estimate and capital and operating costs, and advanced geotechnical work to de-risk the construction phase of the Project. In connection with the funding of Tranche 1, the Company has granted 15,413,508 share purchase warrants to Nebari, with each Warrant exercisable to purchase a common share of the Company at a strike price of C$0.44 per share. Each Warrant granted entitles the holder to acquire one common share of the Company upon exercise thereof and payment of the strike price for a period of three years from the date of issuance. Each Warrant is also subject to an acceleration provision, whereby the Company has the option to require Nebari to exercise up to 12.5% of its Warrants if, for a period of 30 consecutive trading days, the VWAP equals or exceeds a 50% premium above the applicable Warrant strike price. The Warrants and underlying common shares are subject to a hold period under Canadian law that will expire on June 25, 2023.

07:34 EST Focus Financial to be acquired by CD&R for $53 per share in cash - Focus Financial Partners, Clayton, Dubilier & Rice, and Stone Point Capital announced that Focus and CD&R have entered into a definitive agreement for Focus to be acquired by affiliates of CD&R in an all-cash transaction valued at an enterprise value of over $7 billion. The proposed transaction delivers substantial value to Focus' stockholders, who will receive $53 in cash per share, representing an approximately 36% premium to Focus' 60-day volume weighted average price as of the close on February 1, 2023, and an approximately 48% premium to the closing price of the Company's Class A common stock on December 28, 2022. Funds managed by Stone Point have agreed to retain a portion of their investment in Focus and provide new equity financing as part of the proposed transaction.The Special Committee of the Board of Directors has unanimously determined that this transaction is fair to and in the best interests of Focus and its unaffiliated stockholders. The proposed transaction has been approved by the Special Committee, which was formed on November 1, 2022, to evaluate a non-binding offer received from CD&R and to explore alternative transactions. The Special Committee is composed entirely of independent and disinterested directors. The Board of Directors of Focus has approved the proposed transaction on the recommendation of the Special Committee. Closing of the proposed transaction is subject to stockholder approval, regulatory approvals and other customary conditions. The transaction is expected to close in the third quarter of 2023. Focus will cease to be a publicly traded company upon consummation of the proposed transaction. CD&R and Stone Point intend to finance the transaction with fully committed equity financing that is not subject to any financing condition. The proposed transaction is subject to a non-waivable approval of holders of a majority in the voting power of the outstanding shares of common stock held by Focus' disinterested stockholders and provides for a 40-day "go-shop" period expiring at 11:59 p.m. Eastern time on April 8, 2023, which allows the Special Committee and its advisors to actively initiate, solicit and consider alternative acquisition proposals from third parties, with a 10-day extension for parties that submit acquisition proposals during the initial 40-day period that are reasonably likely to lead to a superior proposal. The Company will have the right to terminate the merger agreement to enter into a superior proposal subject to the terms and conditions of the merger agreement. There can be no assurance that this "go-shop" will result in a superior proposal, and Focus does not intend to disclose developments with respect to the solicitation process unless and until it determines such disclosure is appropriate or otherwise required.

07:32 EST Sharecare expands home offerings beyond Medicare Advantage - Sharecare announced it has expanded its home care offerings beyond Medicare Advantage to deliver targeted care management programs and transitional care for high-risk populations across all lines of business within health plans, as well as large employers and health systems. "The right home care provider plays a crucial role in not only improving an individual's quality of life but also preventing more costly medical interventions, such as hospitalization, readmissions, or long-term care facility stays," said Jaffry Mohammed, chief operating officer at Sharecare. "With Sharecare's ability to support members at every point throughout their whole health and well-being journey, including assuming responsibility for the coordination and management of their care within the home, we are uniquely positioned to help solve many of the biggest challenges facing our enterprise partners and their high-risk populations today."

07:31 EST Aura Minerals acquires copper exploration permits in Carajas region in Brazil - Aura Minerals has recently indirectly acquired exploration permits, known as the Serra da Estrela Project in the State of Para, Brazil, in the Carajas region. Aura has made an initial payment of $3 million and if it elects to continue to explore the Serra de Estrela Project, further future payments will be required. Serra da Estrela Project is an exploration permit totaling 9,805 hectares, which includes iron oxide, copper, and gold mineralization targets along a 6 km strike with a surface anomaly. Prior work includes 9 historical mineralized exploration holes totaling 2,552 meters, previously drilled by Anglo American. Aura intends to undertake exploration activities to test the continuity and economic grades of the target. Carajas Mineral Province is one of the most important polymetallic districts in the world and hosts several IOCG deposits such as Sossego and Salobo Mines, Pedra Branca, Igarape Bahia-Alemao, Cristalino, Gameleira and Alvo 118.

07:29 EST Israel Acquisitions announces separate trading of ordinary shares, warrants - Israel Acquisitions announced that, commencing on February 28, 2023, holders of the units sold in the Company's initial public offering may elect to separately trade the Company's Class A ordinary shares and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The Class A ordinary shares and the warrants that are separated will trade on the Nasdaq Global Market under the ticker symbols "ISRL" and "ISRLW," respectively. Those units not separated will continue to trade on Nasdaq under the symbol "ISRLU." Holders of the units will need to have their brokers contact American Stock Transfer & Trust Company, the Company's transfer agent, to separate the units into Class A ordinary shares and warrants.

07:25 EST Clene presents updated VISIONARY-MS Phase 2 trial data - Clene announced updated results from the VISIONARY-MS Phase 2 trial were presented this weekend at the 8th annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2023. The poster titled, "CNM-Au8 Phase 2 VISIONARY-MS Updated Trial Results," contributes to the growing body of evidence supporting improvements in clinical neurologic function and significant paraclinical MRI and VEP findings. The VEP and MRI analyses presented were prespecified exploratory endpoints. VISIONARY-MS investigated the efficacy and safety of CNM-Au8 versus placebo over 48 weeks in stable relapsing remitting multiple sclerosis patients with chronic optic neuropathy. The study was designed to investigate the hypothesis that supporting neuronal energy metabolism protects neurologic function in patients with MS. Nearly all participants were treated with highly effective disease modifying therapies as background standard of care. Due to limited enrollment, 73 of 150, attributed to the COVID pandemic, the threshold for significance was pre-specified at p=0.10 prior to database lock and submitted to the FDA in the statistical analysis plan. Clene announced the topline results of the study in August 2022. The updated multi-focal Visual Evoked Potential findings provide evidence of improved information transmission in the visual system (from the eye to the visual cortex) supported by statistically significant increases in amplitude. The VEP least affected eye was defined as the eye with the shortest latency delay at baseline. Results included all participants with recorded VEP data: mf-VEP amplitude percent change in the least affected eye at baseline - Week 48 least squares mean difference: 9.7%, 95% CI: 3.1% to 16.3%, p=0.0047; mf-VEP amplitude percent change in the most affected eye at baseline - Week 48 LS mean difference: 6.1%, 95% CI: -0.6% to 12.7%, p=0.0730; mf-VEP amplitude percent change across both eyes - Week 48 LS mean difference: 7.9%, 95% CI: 1.4% to 14.4%, p=0.0184; The increased amplitude signal suggests previously impaired neurons subsequently increase information transmission following CNM-Au8 treatment, supporting improved axonal integrity. The primary and secondary endpoints demonstrated improved clinical outcomes in the mITT population, independent of an immunomodulatory effect: The primary endpoint of LCLA change demonstrated significant improvement - Week 48 LS Mean Difference: 3.13; 95% CI: -0.08 to 6.33, p = 0.056; The secondary endpoint of global neurological improvement, mMSFC mean standardized change demonstrated significant improvement - Week 48 LS Mean Difference: 0.28; 95% CI: 0.05 to 0.51, p = 0.0197; CNM-Au8 was well-tolerated, and no significant safety findings were observed.; The exploratory MRI findings provide evidence of brain neuronal structural integrity assessed by diffusion tensor imaging that demonstrated statistically significant results for key metrics of axonal integrity and white matter integrity. Preservation of white matter integrity is associated with decreased cognitive and functional decline in MS patients. Results included all participants with advanced MRI data collection: Fractional Anisotropy change within the whole brain: 0.0029, 95% CI: 0.0048 to 0.0054, p = 0.0199; Fractional Anisotropy change within total Cerebral White Matter - Week 48 LS Mean Difference: 0.0026, 95% CI: -0.0003 to 0.0055, p = 0.0805; Fractional Anisotropy change within total Cerebral Normal Appearing White Matter - Week 48 LS Mean Difference: 0.0025, 95% CI: -0.00025 to 0.0053, p = 0.0737. Since many non-relapsing MS patients continue to clinically deteriorate even while receiving immunomodulatory DMTs, a therapy which improves clinical outcomes, brain structure, and visual system remains a significant unmet medical need in MS.

07:22 EST Cleveland-Cliffs boosts steel product prices by minimum of $100 per net ton - Cleveland-Cliffs announced that it is increasing current spot market base prices for all carbon hot rolled, cold rolled and coated steel products by a minimum of $100 per net ton, effective immediately with all new orders. Cliffs' minimum base price for hot rolled steel is now $1,100 per net ton.

07:20 EST Amarin holder Sarissa discloses 'egregious' equity grants to executives - Sarissa Capital Management issued the following statement regarding Amarin: Sarissa is appalled at this latest act of betrayal of the shareholders by the Amarin board. Sarissa has been urging the Amarin board to release the results of the proxy contest for several days. The board, however, has steadfastly refused, leaving Amarin shareholders to twist in the wind. Now we know why the board has opted to sit on this powder keg of information. Late last week in the stealth of night and right before the General Meeting, the Amarin board disclosed egregious equity grants to executives representing more than 3.6 million shares. CEO Karim Mikhail was given 70% more in equity grants than last year despite the horrendous performance of the company under his leadership. If that is not enough, apparently these grants vest solely based on the passage of time with absolutely no performance criteria. It is important to note that the board did not make these grants consistent with last year's timing but instead made them several weeks later than usual and with no disclosure of any kind in its proxy materials. In so doing, the board ensured that it would not have to disclose this betrayal of shareholders until after the voting deadline in this proxy contest had passed. By making these equity grants in this manner, we believe the board acted in bad faith and engaged in numerous breaches of its fiduciary duties and violations of law. How can a properly functioning board that is abiding by its duties make these grants right before a contested election that could dramatically alter the composition of the board, after the voting deadline has passed, and with no prior disclosure? Bear in mind that at last year's annual meeting more than a majority of the outstanding stock either abstained or voted against "Say on Pay," yet this board determines to change the timing of and significantly increase the quantum of executive equity grants. We believe the answer is simple - this board is violating its fiduciary duties and applicable law. Accordingly, we intend to hold each director personally liable to the fullest extent permissible under applicable law.

07:19 EST Canadian Solar renews EUR 100M note program - Canadian Solar announces that Canadian Solar EMEA Capital Markets, S.A.U., an indirectly wholly-owned subsidiary of Canadian Solar incorporated in Spain, registered on February 24, 2023 its EUR 100M medium term note program in the MARF. Any payment under the notes issued under the note program will be guaranteed by the Company. The notes may qualify as "green bonds" pursuant to the International Capital Market Association, ICMA. Green Bond Principles and the Green Financing Framework approved by the Company. Canadian Solar's Green Financing Framework received a favorable third-party opinion from Sustainalytics. The notes will only be offered and sold to non-U.S. persons outside the United States in reliance on Regulation S under the U.S. Securities Act of 1933. The notes have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction in the United States. The notes may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

07:17 EST Ritchie Bros. sells $244M of equipment in 2023 Premier Global Auction - Ritchie Bros. sold 13,300+ equipment items, trucks, and vehicles at its Premier Global Auction in Orlando, FL, generating $244+ million in gross transaction value last week. The February 20 - 24, 2023 auction attracted 22,600+ people from 80+ countries, with approximately 83% of the equipment selling to U.S. buyers, including 18% purchased by Floridians. The remaining 17% of the equipment was purchased by international buyers from far away as Belgium, Colombia, and Thailand. Auction highlights included 790+ excavators, 500+ truck tractors, 340+ skid steer loaders, 200+ dozers, and 240+ pickup trucks-all assets were sold without minimum bids or reserve prices. "We saw great attendance onsite and online for our Premier Global Auction in Florida, helping us drive strong results for the massive selection of equipment and vehicles available," said Ann Fandozzi, Chief Executive Officer, Ritchie Bros. "Our 200-acre yard was busy all week with customers inspecting items. Meanwhile, customers participating online had access to our new 360-view videos to help with virtual inspections-these were a real hit with customers, so you can expect to see more of these videos for equipment in our auctions going forward."

07:16 EST ProFrac acquires Performance Proppants, upsizes ABL Credit Facility - ProFrac Holding announced that it has successfully completed its acquisition of Performance Proppants, making it the largest in-basin proppant producer serving the Haynesville. ProFrac acquired Performance Proppants for approximately $475M, consisting of $469M in cash and the remainder in shares of ProFrac Class A common stock. Ladd Wilks, ProFrac's Chief Executive Officer, stated, "This transaction greatly enhances ProFrac's vertical integration strategy and demonstrates our commitment to the Haynesville, which we believe is a significant source of long-term opportunity. Additionally, it makes the Company the largest provider of in-basin sand in North America. With four mines totaling 10.4 million tons per year of high-quality proppant production capacity serving the core of the Haynesville, ProFrac will be well positioned to secure supply for our fleets, enhance fleet utilization and add additional value to our customers." Additionally, ProFrac entered into the Fourth Amendment to the ABL Credit Facility. Under the Amended Credit Facility, the aggregate Maximum Revolver Amount was increased from $280 million to $400 million. In connection with the Performance Proppants acquisition, ProFrac borrowed approximately $298 million under the Amended Credit Facility, leaving total availability of roughly $79 million, including letters of credit. Immediately prior to this draw, there were no amounts outstanding under the Amended Credit Facility with the exception of outstanding letters of credit.

07:13 EST Ritchie Bros. independent directors issue letter to shareholders - Ritchie Bros. Auctioneers Incorporated (RBA) issued the following letter from the Company's independent members of its Board of Directors in connection with its March 14, 2023 Special Meeting of Shareholders related to the acquisition of IAA (IAA). "We believe the IAA acquisition is a unique and extraordinary opportunity to execute our growth strategy and deliver outstanding returns to Ritchie Bros. shareholders...We have been impressed with how the entire management team has built and positioned the business over the last three years. Ritchie Bros.' outstanding growth in virtually all key metrics and superior shareholder returns show that we have the right strategic plan and the right team to execute on iti. We have high conviction that the IAA acquisition will propel our progress, growth and value creation even further... Prior to entering the IAA agreement in November, we conducted extensive due diligence with the support of legal and financial advisors as well as third-party consultants. Overall, the Board undertook a 12-month process to evaluate the strategic and financial merits of the deal. We regularly challenged management's assumptions about the strength of IAA's business, IAA's position in the auto salvage market, and the cost synergies and revenue opportunities presented by a Ritchie Bros. + IAA combination... Ritchie Bros. is ready to hit the ground running as soon as the transaction closes... Management has developed a comprehensive integration plan with the right structure, milestones, performance measures and external consultants in place to ensure we successfully bring the companies together... Collaboration with the IAA team has been excellent, and the foundation for a great integration is strong. We are confident in the Ritchie Bros. management team to seamlessly integrate IAA into Ritchie Bros., and the Board will continue to hold management accountable for delivering... We urge you to support your Board and management team as we turn to the next chapter of our journey by voting "FOR" on the WHITE proxy card for all proposals being considered at the Special Meeting on March 14, 2023."

07:08 EST Ardagh Metal Beverage packaging invests in NOMOQ - Ardagh Metal Packaging announces it has acquired a majority share in innovative digital can printers NOMOQ, in a move that extends AMP's industry-leading support of newcomers to the beverage market. The Switzerland-based start-up, founded in 2021, promises printed cans with short lead times and "NO Minimum Order Quantity" - hence the name. Oliver Graham, CEO of Ardagh Metal Packaging, said: "This latest step in our investment programme is a perfect fit for us, especially following the successful integration of Hart Print in North America which encouraged us to seek a similar model in Europe. NOMOQ's offer is innovative, customer-centric, and extraordinarily flexible - areas in which AMP has established a great reputation. Their dedication to creating outstanding packaging for customers of all sizes will enhance our ability to serve early-growth customers in the European market and extend our offering to established customers too."

06:58 EST McEwen Copper announces additional $30M investment by Rio Tinto venture - McEwen Copper Inc., a subsidiary of McEwen Mining Inc. (MUX), announced a binding agreement for an additional $30M investment by Nuton LLC, a Rio Tinto (RIO) Venture, and existing McEwen Copper shareholder. Nuton has agreed to invest $30M to acquire shares of McEwen Copper in a two-part transaction expected to close no later than March 10th, 2023 consisting of: 1. Private placement of 350,000 McEwen Copper common shares, and 2. Purchase of 1,250,000 common shares owned by McEwen Mining in a secondary sale. Proceeds of the subscription and purchase are expected to be approximately $6.5M to McEwen Copper and $23.5M McEwen Mining, respectively. The proceeds of the private placement will be used to advance development of the Los Azules copper project in San Juan, Argentina, and for general corporate purposes. After closing, Nuton will own 14.2% of McEwen Copper on a fully diluted basis, and McEwen Mining will own 51.9%. The transaction values McEwen Copper at approximately $550M. In connection with the Transaction, McEwen Copper and certain of its affiliates entered into an Amended Collaboration Agreement and a Copper Cathodes and Concentrates Purchase Rights Agreement, including that Nuton will have the opportunity to provide local currency funding, in certain circumstances, for advancement of the Los Azules project.

06:56 EST McEwen Copper closes ARS $30B investment by Stellantis - McEwen Copper Inc., a subsidiary of McEwen Mining Inc. (MUX), announced the closing of an ARS $30B investment by Stellantis (STLA). FCA Argentina S.A., a subsidiary of Stellantis N.V., has invested ARS $30B in Argentina to acquire shares of McEwen Copper in a two-part transaction that closed on February 24th, 2023 consisting of: 1. Private placement of 2,850,000 common shares, and 2. Purchase of 1,250,000 common shares indirectly owned by McEwen Mining in a secondary sale. The proceeds of the private placement will be used to advance development of the Los Azules copper project in San Juan, Argentina, and for general corporate purposes. After the closing of the Transaction, McEwen Mining will be separately compensated for the secondary sale by McEwen Copper in U.S. dollars. Giving effect to the upcoming investment by Nuton LLC, also announced today, Stellantis owns 14.2% of McEwen Copper and McEwen Mining owns 51.9% on a fully diluted basis. The Transaction values McEwen Copper at approximately $550M.

06:52 EST Avery Dennison appoints Francesca Reverberi to board of directors - Avery Dennison Corporation announced that its board of directors has appointed Francesca Reverberi as a director, effective February 23, 2023. Reverberi is chief sustainability officer and senior vice president, Sustainable Plastics, at Trinseo.

06:51 EST Nutrien announces TSX approval for renewed share repurchase program - Nutrien announced that the Toronto Stock Exchange has accepted Nutrien's notice to commence a normal course issuer bid to purchase outstanding common shares representing up to five percent of its issued and outstanding common shares. Under the NCIB, purchases of common shares may be made through the facilities of the TSX, the New York Stock Exchange and/or alternative trading systems in Canada and the U.S., or as otherwise permitted under applicable securities laws. The actual number of common shares that may be purchased under the NCIB and the timing of any such purchases will be determined by Nutrien. Nutrien believes that purchasing its own common shares represents an attractive investment opportunity, is in the best interests of the company and is consistent with Nutrien's objective of returning capital to shareholders over time. As of February 15, 2023, Nutrien had 499,243,897 common shares outstanding and, therefore, is permitted to repurchase up to 24,962,194 of its outstanding common shares pursuant to the NCIB. Common shares purchased under the NCIB will be cancelled.The NCIB will be effected in accordance with the TSX normal course issuer bid rules and/or Rule 10b-18 under the U.S. Securities Exchange Act of 1934, as amended, which contain restrictions on the number of common shares that may be purchased on a single day, subject to certain exceptions for block purchases, based on the average daily trading volumes of Nutrien's common shares on the applicable exchange. Subject to exceptions for block purchases, Nutrien will limit daily purchases of common shares on the TSX in connection with the NCIB to no more than twenty five percent of the average daily trading volume of the common shares on the TSX during any trading day. Purchases under the NCIB will be made through open market purchases at market price, as well as by other means as may be permitted under applicable securities laws, including private agreements. Any purchases made by private agreement under an issuer bid exemption order issued by a securities regulatory authority will be at a discount to the prevailing market price as provided in such exemption order. Purchases of common shares may commence on March 1, 2023 and will expire on the earlier of February 29, 2024, the date on which the company has acquired the maximum number of common shares allowable under the NCIB or otherwise decides not to make any further repurchases under the NCIB. Nutrien has entered into an automatic purchase plan with a broker which will enable Nutrien to provide standard instructions and purchase common shares on the open market during self-imposed blackout periods. Outside of these black-out periods, common shares may be purchased in accordance with management's discretion. Nutrien's prior NCIB for the purchase of up to 55,111,110 common shares has expired on February 7, 2023. As of February 15, 2023, Nutrien repurchased an aggregate of 55,111,110 common shares at a weighted-average price of US$84.86 per share, for an aggregate of US$4,676,588,594 under the prior NCIB. Purchases were made on the open market.

06:48 EST Wallbridge Mining closes private placement of flow-through shares - Wallbridge Mining has completed a non-brokered private placement of 37,956,353 national flow-through common shares and 8,000,000 Quebec flow-through common shares for aggregate gross proceeds of $8,621,925. The National FT Shares were issued at a price of $0.185 and the Quebec FT Shares were issued at a price of $0.20. In addition, Agnico Eagle Mines Limited has elected to subscribe for 6,000,000 common shares for aggregate gross proceeds of $1,020,000. Subject to negotiation of the definitive agreement and other customary closing conditions, the AEM Private Placement is expected to close on or about March 10, 2023 and will be undertaken pursuant to certain participation rights set out in a pre-existing participation agreement between the Company and a predecessor of Agnico. The AEM Shares will be issued at a price of $0.17. In connection with the FT Share Private Placement, the Company paid a cash finder's fee of 4% . All securities issued pursuant to the Private Placements will have a four month and one day statutory hold period. The offering is subject to the final acceptance of the Toronto Stock Exchange. The net proceeds from the Private Placements will be used to support the Company's 2023 exploration program at the Company's Detour-Fenelon Gold Trend Property. The financings announced today provide the Company with sufficient cash reserves to fund the previously announced 2023 exploration program on the Detour-Fenelon Gold Trend Property.

06:45 EST First Capital REIT calls Sandpiper statements 'misleading' - First Capital REIT's board of trustees is addressing a February 24, 2023 letter from Samir Manji, CEO of Sandpiper Group and CEO of Artis Real Estate Investment Trust to First Capital's unitholders. The company said, "The Board has repeatedly engaged in good faith with Sandpiper and Artis in an effort to avoid the cost and distraction associated with a proxy contest. As demonstrated in the support and cooperation agreement reached with Vision Capital and Ewing Morris, the Board is willing to find compromises that are beneficial to all unitholders. Unfortunately, the Sandpiper Group's demands continue to be self-serving, unreasonable, not in the best interest of First Capital and its unitholders, and disproportionate relative to their ownership interest. Sandpiper and Artis have a troubling track record. Sandpiper has a history of value destruction at other REITs, including Artis, and a pattern of self-dealing, poor corporate governance and self-enrichment. Artis has been fundamentally changed, to the detriment of its unitholders, by Mr. Manji and his fellow Sandpiper nominees since they acquired control of its board of trustees. Mr. Manji, who is the CEO of both Sandpiper and Artis, has substantial conflicts of interest. Extensive without prejudice discussions preceded our proposal to appoint an independent, non-Sandpiper trustee to the Board. This proposal was an attempt, after much back and forth, to grant the Sandpiper Group representation on our refreshed Board while guarding against the conflicts posed by Mr. Manji. Mr. Manji's characterization of it, including of the time that he had to consider it, is misleading. His outright rejection of this proposal makes it clear that he is intent on installing himself on the Board to advance the interests of Sandpiper and Artis, rather than those of First Capital and its unitholders. The Board continues to focus on ensuring that First Capital is positioned to drive value for all unitholders. It has constructively engaged and continues to engage with all unitholders and has also acted decisively to respond to unitholder feedback in a balanced, pragmatic and considered manner. This is reflected in the REIT's successful Enhanced Capital Allocation and Portfolio Optimization Plan and the refreshed Board that will be presented to unitholders for their support."

06:40 EST K92 Mining reports two 'unplanned' maintenance events at Kainantu process plant - K92 Mining is providing an operational update for its Kainantu Gold Mine in Eastern Highlands Province, Papua New Guinea. During the month of February, the process plant has experienced two notable unplanned maintenance events that cumulatively will have an impact on February and First Quarter production. In early February one of the mill trunnion bearings failed, requiring immediate replacement and resulting in two days downtime, although planned maintenance of other plant equipment was carried out during the stoppage. On February 20th, a limited electrical fire in a cable tray resulted in damage to a number of cables feeding the wet section of the process plant. The cables were all replaced by February 25, and the plant was brought back online and has operated normally since restarting. Although the above incident resulted in a total of 8 days downtime and will impact production for the first quarter, it is not expected that there will be any impact on the 2023 guidance.

06:38 EST Li-Cycle receives conditional commitment for $375M loan - Li-Cycle Holdings announced that Li-Cycle and the U.S. Department of Energy Loan Programs Office, through its Advanced Technology Vehicles Manufacturing program, have entered into a conditional commitment for a $375 million loan. The conditional commitment follows extensive DOE technical, market, financial and legal due diligence and marks another significant milestone endorsing Li-Cycle's development of the first commercial hydrometallurgical resource recovery facility in North America, located near Rochester, New York. This is the first conditional commitment from the DOE ATVM program for a sustainable pure-play battery materials recycling company and the program's main support for the lithium-ion battery recycling industry. The Rochester Hub is expected to become a significant domestic source of battery-grade materials, including lithium, nickel and cobalt, and will be the first-of-its-kind commercial facility in North America. Receiving the conditional commitment is a significant step in the lending process and reflects the DOE's intent to finance the project; however, the Loan remains subject to documentation of long-form agreements and certain conditions will have to be satisfied prior to closing, which is currently expected to occur in calendar Q2 2023. The Loan will have a term of up to 12 years from financial close, and interest on the Loan will be the 10-year U.S. Treasury Rates from the date of each advance for the Loan.

06:35 EST Fisker sees 2023 production up to 42,400 units - The company said, "We maintain our 2023 production target of up to 42,400 units, provided the supply chain delivers per our forecast and we receive homologation in a timely manner. The following information reflects Fisker's expectations for key non-GAAP operating expenses and capital expenditures for the full-year 2023. Fisker is projecting the total of these items to be within a range of $535 million to $610 million. Fisker targets a gross margin range of 8-12% and potentially positive EBITDA for 2023."

06:31 EST GigaCloud non-executive director Huang Xing resigns - GigaCloud Technology announced the changes to the composition of its board of directors. Huang Xing, who served as our non-executive director, resigned as a director of the Board for personal reason, effective December 31, 2022. Mr. Huang's resignation from the Board did not result from any disagreement with the Company, and there are no matters relating to his resignation that need to be brought to the attention of the shareholders of the Company. Mr. Huang's resignation has not affected the normal operation of the Board of the Company. The Board has approved the appointment of Mr. Qian Kainan as a non-executive director of the Company, effective from February 27, 2023, to fill the vacancy on the Board. Mr. Qian has over 20 years of experience in logistics and warehouse management. Since 2018, Mr. Qian served as logistics director of JD Logistics. Upon Mr. Huang's resignation and Mr. Qian's appointment, the Board consists of seven directors, including three independent directors.

06:28 EST Prime Mining announces assay results from drilling outside resource areas - Prime Mining Corp.announces assay results from drilling located outside of the current resource areas, indicating significant exploration upside beyond the forthcoming Q2 2023 mineral resource update. These results are from drill holes targeting previously undrilled or mineralized structures with limited drilling. With continued follow-up in 2023, these initial results have the potential to significantly expand the footprint of the multi-million-ounce Los Reyes high-grade gold-silver deposits across a 15 square kilometre highly prospective mineralized area in mining-friendly Mexico. CEO Daniel Kunz commented, "Our 2023 work will maintain focus on known resource expansion within Guadalupe, Z-T and Central key areas, but we are also extremely excited about the success of the generative exploration results outside of these deposit areas. Further geological interpretation and drilling of five advanced generative areas, highlighted today, along with our extensive remote-sensing and field mapping across Los Reyes, are expected to define new mineralized trends conducive to additional gold-silver deposit discoveries." HIGHLIGHT INTERCEPTS:Fresnillo Area - 1.7 g/t AuEq over 19.3m in hole 22FRE-09, including 5.4 g/t AuEq over 3.6m; Fresnillo Area - 1.5 g/t AuEq over 6.4m in hole 22FRE-04, including 8.2 g/t AuEq over 0.95m AND 1.3 g/t AuEq over 6.0m also in hole 22FRE-04; Orito Area - 1.1 g/t AuEq over 9.4m in hole 22OR-06, including 2.3 g/t AuEq over 3.0 m; Orito Area - 1.1 g/t AuEq over 4.2m in hole 22OR-01, including 2.4 g/t AuEq over 1.1 m; Mariposa Area - 5.2 g/t AuEq over 35.3m in hole 21MA-06 including 42 g/t AuEq over 1.5m; Las Primas Area - 1.8 g/t AuEq over 7.5m in hole 21LP-02, including 17.6 g/t AuEq over 0.35m; Mina 20/21 Area - 18.2 g/t AuEq over 7.5m in hole 21MINA-02.

06:24 EST Evelo Biosciences commences dosing EDP2939 in Phase 2 trial - Evelo Biosciences announced that its first extracellular vesicle product candidate, EDP2939, has progressed to dosing in a Phase 2 psoriasis clinical trial after completing a safety and tolerability review from a first cohort of human volunteers. Safety and tolerability assessment of multiple ascending dose cohorts continues. Mark Bodmer, Ph.D., President of R&D and CSO of Evelo added, "EVs and EDP2939 show great promise as a new type of SINTAX medicine with potential for biologic-like efficacy based on three factors: the high intrinsic potency of EVs in preclinical models; the number and concentration of EVs that can be delivered in a single capsule; and the delivery to the target site of the proximal small intestine. We look forward to reporting EDP2939 psoriasis efficacy results, expected in the second half of this year."

06:19 EST Salem Media announces voluntary redemption of Senior Notes - Salem Media Group announced that it has issued an irrevocable notice of redemption to the trustee of its outstanding 6.75% Senior Secured Notes due 2024. The Notice calls for the redemption in full of the remaining $36.5 million in outstanding aggregate principal amount of 2024 Notes. The redemption date will be March 27, 2023 and the redemption price will be equal to 100% of the principal amount of the 2024 Notes being redeemed, plus accrued and unpaid interest to the redemption date, in accordance with the provisions of the indenture governing the 2024 Notes. The Company expects to pay the redemption price for the 2024 Notes by issuing an additional $44.685 million in aggregate principal amount of its 7.125% Senior Secured Notes due 2028 to certain holders of its 2028 Notes pursuant to a purchase agreement entered into with such holders in connection with the initial issuance of the 2028 Notes. The closing of the Additional Notes Issuance is subject to the satisfaction of customary closing conditions and there can be no assurance that the Additional Notes Issuance will be completed as contemplated or at all.

06:16 EST Organigram launches SHRED X Rip-Strip Hash - Organigram Holding is pleased to announce the launch of SHRED X Rip-Strip Hash. This botanical terpene-infused hash is unlike any other on the market - with 10 pre-cut strips of hash available in a 2g format. This product is a new ultra-convenient hash offering from SHRED that is available in the Tropic Thunder and new Blueberry Blaster flavour profiles.

06:14 EST Fortress Solutions selected by JBG Smith as facilities management partner - Fortress Solutions has been selected by JBG SMITH as its partner for end-to-end facilities management services for their fiber optics, edge data center, and 5G infrastructure across National Landing, known as the first 5G Smart City in the United States.

06:13 EST Ready Capital: Market cap of combined company to be about $2.2B

06:11 EST Ready Capital, Broadmark Realty Capital announce definitive merger agreement

06:10 EST Freyr Battery announces strategic mandate, milestone outlook - FREYR is focused on advancing the following strategic mandates and milestones over the next 12 months: Successfully complete the start of operations at the CQP in 1Q 2023. The capability to produce sample cells from the CQP is expected to accelerate and cement customer dialogues, fortify FREYR's competitive position, demonstrate the scalability of the 24M manufacturing process, and satisfy key technical performance milestones. Accelerate the Company's expansion in the U.S. with a new targeted start of production of 2025 for Giga America to address customer inquiries for fit-for-purpose ESS solutions and to maximize the financial impact of the IRA along with state and local tax incentive packages. FREYR is pursuing fast-tracked development of the previously planned Giga America project schedule to commence production by 2025. Work with leading strategic, financial, and government stakeholders to advance FREYR's capital formation journey. FREYR's intensifying financing processes include prospective project and/or parent-level investment discussions; initial engagement with the U.S. Department of Energy to secure a financial assistance package; advancing the Giga Arctic project financing, and a range of industrial partnership opportunities. Progress construction on the Giga Arctic development while prudently managing capital spending in advance of the anticipated close of the project financing and expected Norwegian and/or EU responses to the IRA. Advance discussions that will further FREYR's ambition to be an industrial scaling partner of choice for leading complementary technology platforms that target distinct and additional end market applications across the ESS, passenger EV, and commercial electric mobility markets. Continue to broaden and augment FREYR's value proposition with the intention to maximize sustainable long-term shareholder value and enhance the Company's competitive position. Key objectives in accordance with this strategy are to continue to forge new strategic and financial partnerships that advance and accelerate the Company's industrialization plan and capital formation.

06:05 EST Dr. Reddy's to acquire Mayne Pharma for upfront payment of $90M - Dr. Reddy's Laboratories (RDY) announced that it has entered into a definitive agreement to acquire the U.S. generic prescription product portfolio of Salisbury, Australia, based Mayne Pharma Group Limited (MAYNF) The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women's health. For the financial period ended June 30, 2022, Mayne Pharma reported total revenue of $111M for the acquired portfolio. Approved high-value products include a hormonal vaginal ring, a birth control pill and a cardiovascular product. Under the terms of the agreement, Dr. Reddy's will acquire the portfolio for an upfront payment of approximately $90M in cash, contingent payments of up to $15M, consideration towards inventory and credits for certain accrued channel liabilities to be determined on the closing date. The closing of the transaction is subject to satisfactory completion of customary closing conditions including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The acquisition will complement Dr. Reddy's U.S. retail prescription pharmaceutical business with limited competition products. It also supports Dr. Reddy's efforts to accelerate and expand affordable medications for patients.

05:31 EST Molekule to acquire Aura Smart Air for $10M in an all-stock merger - Molekule announced it has entered into a definitive agreement to acquire Aura Smart Air, an Israeli-based company currently listed on the Tel Aviv Stock Exchange, in an all-stock merger with a value of approximately $10M. Molekule has the largest range of proprietary and patented, FDA-cleared air purification devices. Under the terms of the Merger, Molekule has agreed to acquire Aura for a total purchase price of approximately 3,519,105 shares of Molekule common stock. Aura, an Israeli-based technology company currently listed on the Tel Aviv Stock Exchange, is the creator of a proprietary, software, sensor and IoT-enabled data-driven air purification system. Consummation of the merger is subject to customary closing conditions, including among others the SEC declaring Molekule's registration statement on Form S-4 effective, the listing of Molekule's common stock on the Tel Aviv Stock Exchange, receipt of Aura shareholder approval, receipt of a tax ruling regarding Israeli withholding tax and receipt of all material third party consents. The merger is expected to close early in the second half of 2023. While Aura will retain its technology development offices in Tel Aviv led by Eldar Shnaiderman, as CTO, several members of the Aura executive team will integrate into Molekule's offices in the U.S., led by Aviad Shnaiderman, as general manager of global commercial sales.

05:20 EST AbbVie receives CHMP opinion recommending approval for upadacitinib - AbbVie announced the European Medicines Agency's, or EMA, Committee for Medicinal Products for Human Use, orCHMP, recommended the approval of upadacitinib, 45 mg and 15 mg and 30 mg for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

05:10 EST Opera announces collaboration with OpenAI - Opera announced a collaboration with the artificial intelligence research laboratory OpenAI. This news comes two weeks after Opera announced its plans to expand its existing AI program by entering the AI-generated content, or AIGC, space through its own solutions and existing partnerships. Through the access to OpenAI's API and its first official generative-AI collaboration announcement, Opera gains access to OpenAI's AI models, as well as personalized support from OpenAI's research team. This will allow the Oslo-based browser company to reshape the upcoming versions of its PC and mobile browsers towards the needs of the future versions of the Web. Opera browser users will be able to benefit from everything AI-backed browsing has to offer. With this collaboration, Opera aims to integrate artificial intelligence and generative computing technologies into its products, reimagining the user experience.